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ABSTRACT
Virus-specific cellular immune responses have been shown to be important in the
control of viral replication in several animal and human virus models. Cells of both
the CD8+ and CD4+ T cell lineages have been shown to play protective roles during
viral infections by exerting effector functions that can kill infected host cells or inhibit
the production and spread of infectious virions. The continued spread of HIV-
infection throughout the world, as well as the lack of a prophylactic HIV-1 vaccine
have generated much interest in HIV-specific cellular immune responses. Recent
technical advances have yielded a tremendous increase in our understanding of
HIV-1-specific immunity, as well as HIV-1 replication dynamics and host cell factors
that shape the course of acute and chronic infection.
Unfortunately, due to small sample volumes and technological limitations , the
study of HIV-1-specific T cell immunity. in infants and children has been difficult. An
improved understanding of the timing, specificity, and intensity of pediatric HIV-
specific T cell responses would contribute to the development of a HIV-1 vaccine for
use in regions of the developing world without access to antiretroviral therapeutics.
In the small number of published studies investigating pediatric HIV-specific
immunity, T cell responses were uncommonly detected in infants. It remains unclear
however, whether the lack of HIV-specific T cells is an accurate reflection of the 
vivo immune state in vertically-infected infants, or rather is a consequence 
reagents and assays ill-suited to the detection of low- level and/or diverse T cell
responses in pediatric subjects.
viii
In the present dissertation , several methodologies were used to investigate HIV-
specific T cell responses in vertically- infected infants and children. HIV-specific CD8+
T cell responses were infrequently detected in a cohort of young infants , but are
commonly detected in older infants and children. Interestingly, CMV-specific CD8+ T
cell responses were detected in several young infants that lacked HIV-specific
responses, suggesting a specific defect in the abiliy of some infants to generate
HIV-specific CD8+ T cell responses. Further experiments characterizing detectable
HIV-1-specific CD8+ T cell responses found that the HIV-1 accessory proteins may
be important targets of the immune response during early vertical infection. The role
of HLA class I genotype and viral sequence are also explored in a pair of vertically-
infected twins with discordant CD8+ T cell responses. Finally, viral isolates from an
infant with a marked shift in gag-specific epitope usage during infancy are analyzed
for the presence of escape mutations.
Gag-specific CD4+ T cell responses were commonly detected in a large cohort of
vertically-infected children. A linear relationship between HIV-1 replication and the
presence and intensity of HIV-specific CD4+ T cell responses was found, but
ongoing HIV-1 replication appeared to blunt CD4+ T cell proliferation.
The data presented in this dissertation describe pediatric T cell immune
responses and how they relate to HIV-1 replication. This information may be useful
to the design of a prophylactic or therapeutic HIV-1 vaccine for vertically- infected
infants and children.
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CHAPTER I
INTRODUCTION
A. Retroviruses.
Retroviruses (family: Retroviridae) are a family of small, enveloped RNA
viruses that infect a wide range of organisms throughout nature. The general
structural hallmarks of the retrovirus virion are: (1) 2 copies of the viral RNA
genome coordinated by nucleocapsid protein surrounded by (2) polymerized
capsid and matrix structural proteins that form a spherical or cone-shaped core,
(3) a host cell derived lipid membrane that surrounds the nucleoprotein core , and
(4) glycoprotein "spike" structures that determine viral tropism and mediate viral
entry (1). The genomic structure of all retroviruses contains a common motif: gag
- pol env. Gag encodes several structural proteins such as capsid and matrix.
The pol gene encodes the major enzymes utilized by HIV-1 to complete its
replicative cycle. Finally, env encodes the envelope-embedded glycoproteins.
Retroviruses that contain additional genes are known as complex retroviruses.
Retroviral genomes range from 7-12 kb in size, and virions are 80-100nm in
diameter.
All retroviruses share several biological features that are uncommonly found
among viruses. Foremost among these is the virally-encoded RNA-dependent
DNA polymerase, also known as reverse transcriptase (RT). RT is responsible
for the generation of a "proviral" double-stranded DNA copy of the retroviral RNA
genome. The discovery of RT not only altered the classical interpretation of the
genetic code (Le. DNA RNA protein), but has led to significant
improvements in molecular biology technology. Second, retroviruses must
integrate their newly-copied DNA genome into a host chromosome. Once
integrated, the retroviral genome becomes permanently entrenched in the
infected cell's genome , and is passed to daughter cells upon cell division. Finally,
retroviruses utilize long terminal repeats , or L TRs, to facilitate integration of the
proviral DNA, recruit transcriptional activators and polymerase machinery, and
polyadenylate mRNA transcripts.
B. Human immunodeficiency virus type 
1. General characteristics and epidemiology.
Human immunodeficiency virus type 1 (HIV-1) is a retrovirus that infects cells
of the human immune system (1). HIV- 1 is a member of the genus Lentiviruses
a group of complex retroviruses that infect primates and many other vertebrates.
The HIV-1 genome is 9.2 kb in length. In addition to the canonical gag pol-
env structure characteristic of all simple retroviruses , the HIV-1 genome encodes
6 additional gene products: nef, tat, rev, vpr, vpu, and vif (Figure 1. 1). The HIV-
accessory proteins serve many enzymatic functions, and most are pleiotropic.
The organization of the HIV-1 genome is ilustrated in Figure 1.2. HIV-1 is not the
only known retrovirus to cause disease in humans. For example, human T cell
leukemia virus type (HTLV- 1), another complex retrovirus
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Figure 1: HIV-1 virion structure (from Robinson , H. L. New Hope for an AIDS
vaccine. 2002 Nature Reviews Immunology 2:239-250.
causes several adult T cell leukemias (2).
HIV- is primarily transmitted through sexual contact, exposure 
contaminated blood products , and intravenous drug use. Additionally, HIV-1 may
be transmitted from mother to child during pregnancy, birth, or through
breastmilk.
HIV-1 was identified in the early 1980s as the causative agent of acquired
immunodeficiency syndrome (AIDS) (3, 4). The hallmark of AIDS is the
progressive loss of CD4+ T cells during chronic HIV-1 infection and susceptibility
to opportunistic pathogens and tumors.
Structural and genetic similarity with the non-human primate Iymphotropic
lentivirus SIV (simian immunodeficiency virus) suggests that HIV-1 was
transmitted from chimpanzees to humans in sub-Saharan Africa. Although the
timing of this species jump is unclear, with the advent of transcontinental travel
HIV-1 has disseminated to all regions of the world. Developing countries have
the highest rates of infection. Sub-Saharan Africa alone accounts for over 70% of
all HIV-1 infections. UNAIDS estimated in 2002 that 42 million people worldwide
are infected with HIV- , with over 5 million new HIV-1 infections per year. Infants
and children are hit especially hard by HIV-1. Although pediatric HIV-1 infections
represent less than 10% of the total number of HIV-1 infections worldwide, 20%
of HIV/AIDS-related deaths in 2002 were in infants and children.
Figure 1.
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Figure 1.2: Organization of the HIV-1 genome. (from Greene , W. , and Peterlin
M. 2002 Nature Medicine 8:673-680).
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2. Viral replication cycle.
The HIV-1 replication cycle may be broken up into several stages. These
include entry/fusion , reverse transcription , integration , gene expression and virion
production. HIV-1 enters permissive host cells when trimeric gp120/gp41 "spike
molecules engage CD4 on the cell surface. This binding event induces a
conformation change within gp120 that exposes a binding domain specific for
chemokine receptors, primarily CCR5 and/or CXCR4 (5). Upon binding of the
chemokine receptor, coiled coil domains within gp41 fold and expose a fusion
peptide that inserts into the host cell membrane (6). This process brings the viral
and cellular membranes into close proximity and allows membrane fusion.
Upon virus-cell membrane fusion, the HIV-1 virion core enters the host cell
cytoplasm. At this stage, the structure is known as the reverse transcription
complex (7). The viral enzyme RT completes a double-stranded DNA copy of the
RNA genome as the entire reverse transcription complex is shuttled towards the
nucleus on actin filaments. Once reverse transcription is complete, the complex
becomes known as the pre-integration complex (8). The primary function of the
pre- integration complex is to allow nuclear import of the viral DNA (and
associated proteins) in non-dividing cells , such as macro phages (9). While the
exact mechanisms that allow nuclear import remain unclear, viral and cellular
factors appear to mediate passage of the pre-integration complex through
nuclear pores (10, 11).
Once the viral DNA and associated proteins have entered the cell nucleus,
integration of the viral genome into the host DNA must take place to allow for
expression of viral gene products and replication of the viral genome. The viral
enzyme integrase catalyses insertion of the linear viral DNA into the host
chromosome. Once accomplished, the "proviral" DNA may either remain
transcriptionally silent (Le. latency), or use viral (tat) and host factors (cyclin T1
NF-KB, NFAT) to allow transcription of viral gene products (12). Complete,
unspliced transcripts of HIV- , as well as singly and multiply spliced mRNA
transcripts are produced and are exported to the cytoplasm (13). Splicing of HIV-
1 transcripts plays an important role in regulating viral gene expression levels
within the infected cell. The viral protein rev plays an important role in the export
of several species of viral transcripts by binding to a region of env known as the
rev response element (RRE) (14).
Following transcription and translation of HIV-1 mRNAs, several proteins
must undergo post-translational modifications. For example, the amino terminus
of gag is myristoylated to allow binding to the plasma membrane (15).
Additionally, the env protein is heavily glycosylated and thereafter cleaved by a
cellular protease to yield gp120 and gp41 (16). As each of the virion components
assembles at the plasma membrane , further enzymatic activities allow for the
formation and budding of infectious HIV-1 virions to complete the viral replicative
cycle.
3. Permissive host cells and viral tropism.
HIV-1 is known to productively infect CD4+ T cells, monocytes , macrophages
and dendritic cells, although the vast majority of circulating virus appears to
derive from the CD4+ T cell compartment. Other cell types , such as B cells and
microglia of the CNS appear to support HIV-1 infection (17), but how these cells
contribute to overall HIV-1 replication remains unclear.
Viral tropism , or the type of cells that may be infected by HIV- , is largely
dependent on sequence variation within the viral envelope glycoprotein (env)
(18). Viral tropism is most commonly defined by identification of which chemokine
co-receptor is used for viral entry. Although HIV-1 may employ other receptors to
facilitate viral entry, the chemokine co-receptors CCR5 and CXCR4 are most
commonly utilized. As the primary reservoir for HIV-1 replication , CD4+ T cells
typically express the chemokine receptor CXCR4 and are infected by li tropic
viruses that bind CXCR4. Conversely, macrophages express CCR5 and are
infected by " tropic" viruses that enter using CCR5. In some individuals
especially those with progressive HIV- 1 replication , dual-tropic viruses , those that
can bind both CXCR4 and CCR5, may be found (19).
4. Viral quasispecies and subtypes.
Due to the high error rate of the HIV-1 RT enzyme , sequence diversity is high
even among circulating viral isolates from single individuals. Viral variants found
within an infected individual are termed quasispecies. Factors such as cell
tropism, replication fitness, antigenicity, and host cell genetics influence the
development of viral quasispecies over time within infected individuals.
Although errors introduced by RT appear to occur randomly throughout the
viral genome, not all mutations allow for productive viral replication. As such
conserved regions within the viral genome, those important for structural or
enzymatic functions, have been identified. Similarity of sequence within these
conserved regions may be used to group HIV-1 isolates documented worldwide
into clades, or groups of viruses with shared backbone sequences. Different HIV-
1 clades predominate in defined geographical regions. For example, clade C is
the predominate HIV-1 subtype found in South Africa whereas clade B HIV-1 is
most common in the United States. The variation found in HIV-1 at the level of
quasispecies (within individuals) as well as clades (among geographic areas)
contributes to the difficulty in developing a vaccine that wil have widespread
effectiveness.
C. Clinical course of natural HIV- 1 infection.
1. Adult HIV-1 infection.
The natural course of HIV-1 infection in adults follows several distinct phases
that ultimately result, in the majority of infected individuals, in a severe
immunodeficiency syndrome and vulnerability to opportunistic infections (Figure
3) (1, 20). Following HIV-1 infection , an acute symptomatic phase lasting
several weeks occurs as the virus replicates to very high levels. During primary
viremia, a significant drop in CD4+ T cell counts is typically observed. Adaptive
components of the immune response , humoral and cellular, are both primed and
develop during this phase. Upon the development of HIV-specific immune
responses, primary viremia peaks and declines up to 3 orders of magnitude to
establish a equilibrium level of viral replication. This "set-point" of HIV-
replication reflects the kinetics of viral production from productively-infected cells
and viral clearance by host immune responses. The decline in viremia appears to
occur with the generation of HIV-specific CD8+ T cell responses (21). The level of
HIV-1 viremia that is established at the set-point is prognostic of the rate of
progression to the symptomatic phase of chronic HIV-1 infection (22).
Following the acute phase of HIV- infection, chronic HIV- infection is
characterized by a long, asymptomatic period, lasting on average 10 years. Many
host cell and viral factors influence the length of asymptomatic HIV-1 infection,
including HLA class I genotype , chemokine co-receptor expression patterns and
polymorph isms, and viral deletions or mutations that modulate tropism and the
fitness" of viral replication within the host. During this period, CD4+ T cell counts
gradually erode and leave the infected individual susceptible to opportunistic
infections and tumors when CD4+ T cell counts drop below 200 cells/ L of blood.
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2. Pediatric HIV- 1 infection.
As stated previously, HIV-1 may be transmitted from mother to child , either
during pregnancy (in utero), during labor (peripartum), or through breastmilk. The
vast majority of pediatric HIV-1 infections are the result of vertical transmission
(i.e. from mother to child) of the virus. In the absence of antiretroviral therapy,
approximately 25% of infants acquire HIV-1 from the mother. Transmission rates
are higher in developing countries.
Interestingly, the course of primary HIV-1 infection in vertically-infected infants
is markedly different than that observed in adults (Figure 1.4). In contrast to the
resolution of primary viremia and establishment of a viral set-point as observed in
adults, pediatric HIV-1 infection is characterized by sustained high-level HIV-
replication during the first several years of life (23 , 24). Several factors may
contribute to high levels of viral replication during the first years of life. First, the
overall pool of CD4+ T cells, the main substrate for HIV-1 replication, is larger
than that found in adults (25). Second, thymic mass relative to overall body mass
is high in infants, and thymocytes have been shown to be susceptible to HIV-
infection (26). Finally, absent or delayed HIV-specific immune responses may not
allow for control of primary viremia (27).
The rapid progression of HIV-1 infection in infants and children contributes to
the higher mortality observed in this population. Approximately 15% of untreated
HIV- infected infants die by 4 years of age.
Figure 1.
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Figure 1.4: HIV-1 replication in untreated vertical infection (from Shearer
, W.T. 
al. 1997 N Engl J Med 336 (19):1337-42).
3. Antiretroviral therapy.
Significant advances in the development of antiretroviral therapeutics that
target several HIV-1 enzymatic processes have dramatically improved the
prognosis of HIV- infected individuals in developed countries (28). These
include reverse transcriptase, protease, and entry inhibitors. Antiretroviral
therapies, especially when used in combination, have greatly improved the
prognosis and quality of life of HIV- infected individuals, both adult and pediatric
(29, 30). Moreover, administration of therapies during labor has been shown to
dramatically lower the rate of vertical transmission. Unfortunately the high cost of
these drugs, coupled with poor clinical , social, and political infrastructures in
developing nations, have blunted their impact on the HIV- epidemic.
Furthermore, the development of resistance mutations to each class of
antiretroviral therapy available complicates the administration of these drugs and
necessitates ongoing development of novel HIV- inhibitors. The failure of
antiretroviral therapy to stem the growing tide of HIV-1 infections throughout the
world underlines the need for the development of prophylactic and therapeutic
vaccine strategies to stimulate durable, broad, and potent HIV-specific immunity.
D. T cell immunity during pediatric HIV-1 infection.
1. CD8+ T cell responses.
Human immunodeficiency virus type 1 (HIV- )-specific CD8+ T cell responses
have been shown to play an important role in controllng HIV-1 viral replication
during both acute and chronic stages of adult infection (21, 31-33). The use of
ART has greatly enhanced the clinical status of many HIV- infected individuals,
and several studies have indicated that early administration of therapy during the
acute phase of viral infection can preserve HIV-1-specific immunity in adults (34).
While the clinical benefit of early ART in vertically- infected neonates is clear
the reduction in HIV-1 viral replication during the initiation of a primary response
may impair the generation of HIV-1-specific cellular immunity. There appears to
be a lack of persistent HIV-1-specific CD8+ T cell responses in infants who
receive early ART (27). In a cross-sectional study, Spiegel et al. have also
described reduced CD8+ T cell frequencies in infants and children on ART (35).
Potent therapy may reduce the availability of viral antigen for processing and
presentation to HIV-1-specific CD8+ T cells thus impairing the generation and
expansion of HIV-1-specific memory populations. These populations may be
important to help control viral replication during periods of viral breakthrough
secondary to poor medication adherence, medication intolerance, or drug
resistance.
A better understanding of pediatric CD8+ T cell responses to HIV-1 antigens,
as well as how these responses are maintained during the course of ART , may
contribute to the development of strategies that boost the quantity and quality of
HIV-1-specific CD8+ T cells while still allowing for the continued clinical benefit of
ART.
---------
2. CD4+ T cell responses.
Greater insight into HIV-specific CD4+ T cells may be particularly important
since CD4+ T cells serve as a major substrate for HIV-1 replication, as well as
provide antiviral helper or effector functions (36, 37). Many studies have
investigated HIV-specific CD4+ T cell responses during adult infection , but data
regarding pediatric CD4+ T cell responses are limited. Previous efforts, using
Iymphoproliferative assays, failed to detect, or detected only low- level CD4+ T
cell responses in vertically-infected infants (27, 38). In general, adult studies
have failed to detect vigorous HIV-specific CD4+ T cell proliferation in individuals
with active HIV-1 replication or progressive disease (39 , 40), but have detected
the presence of HIV-specific CD4+ T cells that secrete IFN-y (41-45). Although
these studies have made significant contributions to our understanding of HIV-
specific CD4+ T cells and their functional responses, the quality, timing, and
longevity of pediatric CD4+ T cell responses remain poorly understood.
E. Thesis Aims.
The objective of this thesis dissertation was to characterize HIV-1-specific T
cell immunity in vertically- infected infants and children. As previously discussed
little is known about the timing, magnitude, breadth , and specificity of pediatric
cellular immune responses against HIV-1, and how these responses may differ
from those generated against other viruses commonly acquired during infancy or
from T cell immunity generated in HIV- infected adults.
In Chapter 3, the specificity and frequency of HIV-1-specific CD8+ T cell
responses in 17 vertically- infected infants who initiated ART between 1-
months of age are presented. CMV-specific responses were also followed in 
young infants coinfected with HIV-1 and CMV. Our data show that CD8+ T cell
responses are less commonly detected in young infants (c:6 months of age) than
in older infants prior to treatment. Interestingly, CMV-specific responses were
detected in several young infants despite low frequency or undetectable HIV-
specific responses. These findings suggest a specific defect in the generation of
HIV-1-specific CD8+ T cell responses in young HIV- infected infants.
To further investigate HIV-1-specific CD8+ T cell immunity during infancy,
several additional methods and reagents were used to characterize CD8+ T cell
responses, viral replication, and viral sequence in a second cohort of HIV-
infected infants. As illustrated in Chapter 4 , HIV-specific CD8+ T cell IFN-
responses were detected in the majority of infants prior to initiation of ART using
an expanded panel of HIV-1 antigens. CD8+ T cell IFN-y responses targeting
HIV-1 accessory proteins (nef, tat, rev, vif, vpr) accounted for nearly half of all
detectable responses. The hierarchy of responses detected was gag, nef env 
pol, tat, rev , vpr vif. Quantification of HIV-specific CD8+ T cell responses also
ilustrated the importance of HIV-1 accessory proteins in the overall HIV-specific
response. To further characterize HIV-specific CD8+ T cell IFN-y responses
during infancy, a pair of infected twins and an infant with strong HIV-1 specific
responses were studied in detail. Data from these experiments reveal the strong
If,
influence of HLA class I genotype as well as viral sequence in shaping the HIV-
specific CD8+ T cell response.
Finally, to address the role of HIV-specific CD4+ T cell responses during
pediatric HIV- infection, a large cohort of children was analyzed for the
presence of HIV-1 and CMV-specific CD4+ T cell responses. As presented in
Chapter 5, HIV-1-specific CD4+ T cell responses were commonly detected in the
cohort, although they were detected more frequently and at higher intensities in
those children with ongoing HIV-1 replication. By contrast, CMV-specific CD4+ T
cell responses were detected most frequently and at higher intensities in those
children with undetectable HIV- replication, suggesting that ongoing HIV-
replication had a detrimental impact on the generation and/or maintenance of
other virus-specific CD4+ T cell responses. Analysis of proviral 2-L TR circles
revealed that only low levels of HIV-1 replication are required to drive HIV-
specific CD4+ T cell responses, suggesting a relationship between HIV-
replication and the presence of CD4+ T cell immunity. HIV-1 replication was
associated with increased frequencies but impaired in vitro proliferative capacity
of HIV-specific CD4+ T cells.
These data have important implications for the treatment and management of
HIV- infected infants and children, as well as for the design of a vaccine that
may allow for improved long-term control of HIV-1 infection.
CHAPTER II
MATERIALS AND METHODS
A. Study populations.
Specific information and data concerning the pediatric study populations
studied during the course of thesis research are presented at the beginning of
each chapter in the results section. In all cases, written informed consent was
obtained from the legal guardian of all study participants in accordance with the
Institutional Review Board of the University of Massachusetts Medical School.
The guidelines of the U.S. Department of Health and Human Services governing
experimentation in humans were followed.
B. Diagnosis of HIV- 1 infection.
Diagnosis of HIV- infection was made if HIV-1 testing on at least two
separate blood samples was positive. In children older than 18 months of age,
HIV-1 serology (ELISA with confirmatory Western blot) was used to screen for
HIV-1 infection. Many of the children in the cohort were diagnosed younger than
18 months of age, in which case the polymerase chain reaction was used to
detect HIV-1 provirus in PBMC. Viral isolation was used to confirm infection in all
children.
C. Quantification of plasma HIV-1 RNA copy number by reverse transcriptase
(RT)-mediated PCR.
Measurements of plasma viral copy number presented in Chapter 3 were
made using the NuciiSens quantification assay (Organon Teknika, Durham, NC)
according to the manufacturer s instruction. The lower limit of detection is 400
viral RNA copies/mL plasma.
Measurements of plasma viral copy number presented in Chapters 4 and 5
were made using Amplicor quantification assay (Amplicor; Roche Diagnostics
Branchburg, NJ) according to the manufacturer s instruction. Plasma samples
with values below the detection limit of the standard assay (c:400 copies/mL)
were subsequently tested using 450j.L of plasma and a modified assay with a
detection limit of 50 HIV-1 RNA copies/mL.
All assays were performed in a single laboratory that participates in an
ongoing quality certification program for HIV-1 RNA quantitation sponsored by
the National Institutes of Health.
D. Diagnosis of CMV infection.
CMV infection status was determined by ELISA for presence of anti-CMV IgG
in serum samples taken after 18 months of age. Serological analysis was
performed by the University of Massachusetts Serology Laboratory. Congenital
CMV infection was diagnosed in infant A13 through CMV urine cultures at c:1 mo
of age.
E. Peripheral blood and cel/lines.
PBMC were isolated from whole blood using the Ficoll-Paque (Pharmacia,
Piscataway, NJ) density centrifugation method and viably cryopreserved in
RPMI1640 containing 10% DMSO. For use in the ELiSPOT assay, cells were
thawed and washed twice in RPMI1640 media supplemented with 10% fetal calf
serum , 25mM HEPES, and 10mg/L gentamicin (R10 media) prior to counting.
Autologous B-LCL were generated for each study participant by EBV/cyclosporin
A transformation. B-LCL were maintained in R10 media.
F. Recombinant vaccinia vectors.
Recombinant vaccinia virus vectors containing single HIV-1 clade B gene
products (gag (vAbT 141), pol (vCF21), env (vAbT 271), nef (vT23), tat (vT279),
rev (vT320), vpr (vT100), and vif (vT28)) were supplied by Therion Biologics
(Cambridge , MA). Recombinant vaccinia virus vectors containing the CMV gene
products pp65 or gB were supplied by Willam Britt (University of Alabama,
Birmingham). Wild-type vaccinia virus (NYCBH strain; Therion Biologics) was
used as a negative control.
For each recombinant vaccinia vector used in the ELiSPOT assays , 5x10
1 x1 0 LCL cells were infected at MOl = 10 and allowed to incubate 16 -
hours (overnight) at 37 C in 5% CO . Prior to addition to the ELiSPOT plate
infected B-LCL were washed twice in R10 media and counted.
G. Detection of Ag-specific CDS+ T cells using modified ELISPOT assay.
modified IFN-y ELiSPOT assay was developed based on a previously
published method (46). Our assay used autologous B-LCL as antigen-presenting
cells to assay for HIV-1-specific release of IFN-y by antigen-specific CD8+ T cells.
Prior to the addition of cells, a 96-well flat bottom plate (MAIPN1450 , Milipore,
Bedford, MA) was coated with 1 mg/mL of anti- IFN-y mAb (D1 K , Mabtech , Nacka,
Sweden) and allowed to sit overnight at 4 C. After washing the plate with cold
phosphate-buffered saline (PBS), each plate was blocked for non-specific
antibody binding by addition of 200 j.L/weil of R10 media for 2 hours at 37
Fifty thousand PBMC from each timepoint were added, in duplicate, for each
HIV-1 recombinant vector tested. Ten thousand vaccinia recombinant-infected B-
LCL were added to appropriate wells to bring the total volume in each well to 100
j.L. This constituted an E:T ratio (PBMC:B-LCL) of 5:1. To ensure assay
consistency, all study timepoints (per study subject) and vaccinia recombinant
targets were assayed on the same ELiSPOT plate. Each plate was incubated
16-20 hours overnight at 37 C in 5% CO . Following overnight incubation , the
plate was washed with cold PBS and 0.5 mg/mL of a secondary, biotinylated
anti- IFN-y mAb (7-B6-1, Mabtech) was added for 3 hours at room temperature.
The plate was washed again with cold PBS, and 0. mg/mL of a
strepavidin/alkaline phosphatase conjugate (SA-ALP , Mabtech) was added for 2
hours at room temperature. Spot-forming cells (SFC) were visualized after
alkaline phosphatase color development (BioRad , Richmond, CA).
SFC were counted using a stereoscope (American Optical Corp.
, Buffalo , NY)
at 20x magnification. SFC counts were averaged between duplicate wells to
obtain an experimental value for each HIV-1 gene product/PBMC timepoint
combination studied. ELiSPOT responses are referred to in the text as SFC/10
PBMC over vaccinia background. Two criteria were used to define positive
responses. First, each well (from a duplicate pair) must have a minimum of 3
SFC (corresponding to 60 SFC/10 PBMC). Second, the experimental SFC
frequency must be 3 standard deviations above the average of all duplicate
negative control wells (vaccinia NYCBH) performed on the plate. If both
conditions were not met responses were not considered positive.
PMA/ionomycin stimulation of PMBC samples from all study timepoints served as
positive controls for IFN-y expression.
H. Overlapping peptide pools.
To faciltate fine mapping of CD8+ T cell epitopes , 121 overlapping peptides
spanning HIV-1 gag (clade B HXB2 isolate) were pooled and used in the
ELiSPOT assay (NIH AIDS Research and Reference Reagent Program
, Division
of AIDS , NIAID , NIH , Bethesda , MD). Each peptide was 15 a.a. in length, and
overlapped adjacent peptides by 11 a.a. To prepare the peptide pools, individual
peptides were dissolved at 11 mg/mL in DMSO. An 11 x11 matrix was
constructed, with each peptide represented in exactly two pools. Equal volumes
of 11 peptides were placed into each pool , diluting the concentration of each
individual peptide within the pool to 1 mg/mL. Autologous B-LCL were incubated
for 1 hour with 20/-g/mL (final concentration per peptide) of each pool for use as
antigen-presenting cells in an ELiSPOT assay.
,. CDS+ T cell depletion.
Cryopreserved baseline samples on patients A 10 and B2 were depleted of
CD8+ T cells using magnetic bead separation according to manufacturer
specifications (Dynal ASA, Oslo, Norway). FACS analysis (using anti-CD4+ and
anti-CD8+ antibodies) was used to confirm that the small lymphocyte population
consisted of less than 4% CD8+ cells after depletion (Becton Dickenson
FACScan). CD8+ T cell depleted and non-depleted PBMC aliquots were then
used in the ELiSPOT assay as previously outlined.
J. Enumeration of lymphocyte subsets in the peripheral blood.
The relative percentages of CD3+CD4+ and CD3+CD8+ lymphocytes in the
peripheral blood were enumerated by direct immunofluorescence with fluorescein
isothiocyanate (FITC) or phycoeryhrin (PE) conjugated mouse monoclonal
antibodies (BD Immunocytometry Systems, San Jose, CA). Samples were
analyzed by flow cytometry using CELLQUEST softare (FACScan, BD
mmu nocytometry Systems).
K. Detection of Ag-specific CD4+ T cells by intracellular cytokine staining for IFN-
Antigen-specific CD4+ T cell responses were detected using an intracellular
cytokine staining assay. Briefly, anti-CD28 and anti-CD49d monoclonal
antibodies (3Jlg/mL; BD PharMingen, San Diego, CA) were added to 0.5mL fresh
heparinized whole blood aliquots from each study subject and incubated with the
following protein antigens: HIV- 2p55 and CMV pp65 (5Jlg/mL; Austral
Biologicals, San Ramon , CA). Two additional whole blood aliquots (both
;'1
containing the anti-costimulatory antibodies) were set up as negative (no antigen)
and positive controls (Staphylococcal enterotoxin B , 4Jlg/mL; Toxin Technology,
hours at 37 C and 5% CO . Brefeldin A (BD PharMingen) was added for the final
Sarasota , FL) for each study subject. Samples were incubated at a 5 slant for 6
4 hours of incubation. After incubation, EDTA was added to each tube and
:1,
II!
samples were fixed (FACS Lysing Solution; BD Immunocytometry Systems) and
:1'
permeabilized (FACS Permabilzing Solution; BD Immunocytometry Systems) II:
according to the manufacturer s instructions. Each sample was stained with the
following conjugated Abs: peridinin chlorophyll-anti-CD4, FITC-anti-CD45RO,
':'
i\'
phycoeryhrin-anti-CD69, and allophycocyanin-anti-IFN-y (BD Immunocytometry II:
Systems and BD PharMingen). Flow cytometry analysis was performed within 24
hours of sample preparation as described above. Samples were gated on
CD4+/CD45RO+ small lymphocytes and analyzed for CD69 and IFN-y
expression. Results are expressed as the percentage of CD4+/CD45RO+ small
:",
lymphocytes expressing CD69 and IFN-y. Antigen-specific CD4+ T cells were not
detected in the CD45RO- population.
All experimental samples exhibited strong CD4+ T cell IFN-y responses to
SEB. Responses in the absence of antigen (no antigen controls) ranged from 
05% (mean: 0.02%). Experimental responses were considered positive if they
exceeded 0.06% (two standard deviations above the mean negative control
value ).
After stimulation with HIV-1 p55 antigen , CD4+ T cellIFN-y responses in HIV-
1-uninfected adults (median: 0.01%; range: 0.01- 03%) did not differ from
background responses (no antigen control; median: 0.01 %; range: 0-0.04%).
Similarly, CMV pp65-specific CD4+ T cells were detected in two HIV-
uninfected, CMV seropositive donors, but were not detected in CMV
seronegative donors.
L. Lymphoproliferative assays.
Lymphoproliferative assays were performed as previously described (27 , 39,
44) with the following modifications. PBMC were separated from fresh whole
blood by Ficoll-Paque (Amersham Pharmacia Biotech, Piscataway, NJ) density
centrifugation and were incubated with HIV- 2 p55 and CMV pp65 protein
antigens at a concentration of 10f.g/mL (Austral Biologicals). PBMC were
incubated in triplicate wells (10 cells/well) for 7 days before harvesting. Cells
incubated with media alone or pokeweed mitogen (PWM; 10f.g/mL; Sigma-
Aldrich , St. Louis, MO) served respectively as negative and positive controls.
Plates were analyzed (Wallac 1450 MicroBeta Trilux; Perkin Elmer Wallac,
Gaithersburg, MD) and stimulation indices (81) were defined as the ratio of the
mean counts per minute of the stimulated well to the mean counts per minute of
the negative control wells. Assays were considered valid only if the counts per
minute measured in each of the negative control wells were less than 1 000.
Stimulation indices greater than 3 were considered positive responses.
M. Detection of HIV-1 2-L TR circles in PBMC.
PBMC pellets were resuspended in buffer P1 and extrachromosomal DNA
was purified using a QIAprep spin miniprep kit (Qiagen, Valencia, CA) using the
modifications recommended by the manufacturer for the isolation of low copy
number plasm ids. Final elution of the purified DNA was in 120J.L elution buffer
preheated to 70 C. 2- TR junction sequences were amplified from 30J.L of
extrachromosomal DNA in a 50J.L reaction containing 1X HotStarTaq buffer,
200J.M deoxynucleotide triphosphates, 500nM each primer, 200nM fluorogenic
probe and 2U of HotStarTaq (Qiagen). The reverse and forward primers were 5'
AGACCAGA TCTGAGCCTGGGA-3' and 5' -GT AGTTCTGCCAA TCAGGGAAG-
, respectively, which annealed to nucleotides 13 to 34 (HIV-1 L TR R region)
and nucleotides 8770 to 8749 (HIV-1 L TR U3 region) of HIV-1LAI (Genbank
accession number K02013). The fluorogenic probe (5'
AGCCTCAA T AAGCTTGCCTTGAGTGC- ) was complementary to nucleotides
67-93 of HIV-1LAI and was modified with 6-FAM (6-carboxyuorescein) reporter
dye on the 5' end and 6- T AMRA (6-carboxytetramethylrhodamine) quencher dye
on the 3' end. After an initial denaturation/enzyme activation step (95 C, 10 min),
PCR amplification proceeded for 45 cycles (95 , 15s; 62 C, 1 min). To control
for the effect of sequence polymorphisms at primer binding sites and to allow for
the quantitation of total viral genomes, amplifications were performed using
primers that were reversed in orientation to those listed above and a different
probe (5' - FAM-AGTGGCGAGCCCTCAGA TGCTGC-6- T AMRA- which
annealed to nucleotides 9103-9081 of HIV-1LAI. Copy numbers were determined
from a standard curve generated by the quantitation softare of the ABI Prism
7700 sequence detection system. The assay limit of detection was 1 copy.
N. Generation and use of HLA class I (A 0201) tetramers.
Tetramers of HLA A*0201 bound to the gagp17 peptide SL9 (a.a. 77-85,
SL YNTVATL) were generated as previously described (27). Briefly, HLA A*0201
heavy chain 2-microglobulin , and SL9 peptide were refolded (monomer) and
biotinylated. Tetramers were formed by the addition of a streptavidin-
allophycocyanin conjugate (BD PharMingen).
Fresh whole blood samples or viably cryopreserved PBMC were stained with
1/-L of tetramer as well as 10/-L each of anti-CD3-PerCP (BD Immunocytometry
Systems) and anti-CD8-FITC (Sigma-Aldrich) to allow discrimination of epitope-
specific CD8+ T cells. Samples were fixed (FACS Lysing Solution; 
Immunocytometry Systems), washed , and analyzed within 24 hours.
O. Sequence analysis of CD8+ T cell epitopes in HIV- 1 gag.
HIV-1 RNA was isolated from patient plasma samples using the QIAamp Viral
RNA Mini Kit (Qiagen, Valencia, CA). cDNA was generated using random
hexamers or a reverse primer specific for the 5' end of pol (RTRD: 5'
CTGTCCACCA TGCTTCCC- ) to allow for complete amplification of the gag
gene (GeneAmp RNA PCR Kit; Applied Biosystems , Branchburg, NJ). Following
cDNA synthesis, PCR reactions were used to amplify the gag SL9 (a.a. 77-85;
forward primer: CAGT A TT AAGCGGGGGAGAA TT - reverse:
CCACTGTGTTTAGCATGG- ) and W9 (a.a. 362-370; forward primer: 5'
A TGAGAGAACCAAGGGGAAGTGA- reverse:
TGTTGGCTCTGGTCTGCTCT- epitopes (HotStarTaq DNA Polymerase;
Qiagen). A second , nested PCR reaction was performed to further amplify these
regions (SL9, forward primer: 5' GTATGGGCAAGCAGGGAGCTAGAA-
reverse: CTGTTGTTTCCTTGTGTCAGC- ; W9, forward primer: 5'
AT AA TCCACCT A TCCCAGT AGGAGAA T - reverse:
CTTTGCCACAA TTGAACACTT - Following verification specific
amplification by gel electrophoresis, the gag amplicons were ligated into pCR2.
plasmids and transformed into INVaF' cells (TA Cloning Kit; Invitrogen , Carlsbad,
CA). Clones were selected (p-gal) after overnight incubation on ampicilin-infused
LB plates. Plasmid DNA was amplified overnight in kanamycin-infused slant
cultures and isolated using the QIAprep Spin Miniprep Kit (Qiagen). Following
restriction digest analysis , clones were amplified (Platinum Pfx DNA Polymerase;
Invitrogen) and purified (QIAquick PCR Purification Kit; Qiagen). A Big Dye 3.
sequencing PCR reaction was performed using multiple primers spanning the
gag gene, or single primers specific to epitope/regions of interest (Applied
Biosystems). After ethanol precipitation , all samples were sequenced by the
University of Massachusetts Center for AIDS Research Sequencing Facility.
P. Statistical analysis.
All data sets were tested for statistical differences using the Wilcoxon Rank
Sum (univariate) or Kruskal-Walls Rank Sum (multivariate) nonparametric tests
for non-Gaussian distributed data. All tests were two-tailed and p-values equal to
or less than 0.05 were considered significant. All analyses were performed using
Axum 7.0 softare (MathSoft, Cambridge , MA).
CHAPTER II
Infrequent Detection of HIV- Specific, but not Cytomegalovirus-Specific, CD8+ T
Cell Responses in Young HIV- lnfected Infants.
A. Study population characteristics.
Seventeen infants with vertical HIV- infection were studied prior to and
following combination antiretroviral therapy. All but one infant were treated with
zidovudine, lamivudine, and ritonavir and were participants in the Pediatric AIDS
Clinical Trials Group (PACTG) Protocol 345, a clinical trial designed to evaluate
the pharmacokinetics of ritonavir in young infants and the virologic and
immunologic consequences of early therapy. Infant A 13 received stavudine,
lamivudine, nevirapine, and nelfinavir through PACTG Protocol 356. Inclusion in
the present study was based solely on PBMC sample availabilty. Clinical and
immune status, viral loads, and response to therapy in our study population did
not differ from the trial group as a whole.
Characteristics of the study population are presented in Table 3. 1. Age at
study entry ranged from 1 month to 23 months. Subjects were divided into two
groups based on age at therapy initiation: c:6 months of age (group A, n=13;
mean age: 2.9 months) and ::6 months of age (group B, n=4; mean age: 17.
months). PBMC samples from study weeks 0 (baseline), 8 or 12 , 24 or 28, and
48 were employed in the analysis. Baseline CD4+ T cell counts were c:25% in
Table 3.
Age at Virologic %CD4+ T Plasma Viral
Patient baseline responder cells at Load at
status baseline Baseline
96,000
290,000
610 000
92,000
320,000
200,000
830,000
660,000
160,000
A10 560,000
A11 160,000
A12 600 000
A13 132 000
23. 000
23. 1700
15. 13,000
82,000
N/A Uninfected
N/A Uninfected
N/A Uninfected
N/A Uninfected
24. N/A U ninfected
N/A U ninfected
N/A
41,000
000
N/A
Table 3.1: Study population characteristics. Seventeen infants with vertically-
acquired HIV-1 infection (groups A and B). Six HIV-uninfected, age-matched
infants (group C) and 4 HIV- infected infants and children (group D) served as
control subjects.
only 2 infants. Six uninfected infants born to HIV- infected women, in the same
age range as the 17 study infants, were used as control subjects (group C; age
range: 2-24 months, mean age: 7.6 months). Samples from four children (group
D; age range: 14-65 months, mean age: 44 months) with established HIV-
infection were used to validate the B-LCL ELiSPOT assay.
Seven infants were classified as virologic responders (R) as plasma viral load
fell to undetectable levels (c:400 copies/mL) by 16 weeks on therapy and
remained undetectable at all subsequent timepoints. An additional 6 infants
controlled viral replication by week 16 but failed to keep viral replication below
400 copies/mL for the entire course of the study and were coded as incomplete
responders (IR). The remaining 4 non-responder (NR) infants did not control viral
replication.
B. Autologous B-LCL can be used as antigen-presenting cells in an ELISPOT
assay.
Previous studies using limiting dilution assays or non-specific in vitro
stimulation have shown that cytotoxic T cell responses are uncommonly detected
in the PBMC of young vertically-infected infants (47, 48). The IFN-y ELiSPOT
assay has been widely used to detect functional antigen-specific CD8+ T cell
responses after minimal in vitro stimulation in several viral systems. To increase
the chances of detecting HIV-1-specific responses in the present study using the
EllS POT assay, a panel of 4 recombinant vaccinia vectors carrying HIV-1 gag,
pol , env , and nef were used. This strategy avoids limiting the breadth of detected
responses to previously defined class I HLA-restricted HIV-1 epitopes.
After evaluation of this assay system using adult PBMC (data not shown),
PBMC from 4 HIV- infected children (group D) were tested (Fig. 3. 1a). IFN-
ELISPOT responses were detected in all 4 children against HIV-1 gag (range:
240-1480 SFC/10 PBMC, mean: 750 SFC/10 PBMC). Env-specific responses
(range: 230-770 SFC/10 PBMC, mean: 580 SFC/10 PBMC) were also detected
at similar levels in 3/3 children studied. While the response to vaccinia alone was
180 SFC/10 PBMC in one child (D2), all other background responses were low
(60 SFC/10 PBMC or less; representing c:3 SFC per well at 5x10 PBMC per
well).
C. HIV- 1-specificity of CD8+ T cell responses.
To confirm that IFN-y ELISPOT responses detected against these HIV-
recombinants were HIV-1-specific, 6 uninfected infants (group C) ranging in age
from 2-24 months were also studied. Responses to HIV-1 gene products were
not detected in any of the uninfected infants (Fig. 3. 1 b).
D. HIV-1-specific CD8+ T cell responses prior to antiretroviral therapy.
Prior to the initiation of antiretroviral therapy, IFN-y responses to HIV-1 gene
products were detected in only two infants (15%) c: 6 months of age (Fig. 3.2).
Infant A5 generated a low-level response to nef (80 SFC/10 PBMC). Infant
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Figure 3.1: Detection of HIV-1-specific IFN-'Y responses using a modified
ELiSPOT assay. (a.) IFN- r responses were detected in four HIV- infected
children with established infection against HIV-1 gag and env. (b) Uninfected,
age-matched infants did not generate IFN-'Y ELiSPOT responses against a panel
of HIV-1 recombinant vaccinia vectors. All responses are listed as SFCs per
million PBMCs. Single time points were tested for HIV-1-specific responses in
each subject. Blank spaces indicate experiments not performed.
' .
A 10 generated responses to both the env and nef gene products (720 and 700
SFC/10 PBMC, respectively). Conversely, IFN-y responses to at least a single
HIV- 1 gene product were detected at baseline in all 4 infants (100%) 6 months
of age (group B). Three of four older infants generated responses against single
HIV-1 gene products (pol=2 , nef=1), while responses to gag (920 SFC/10 ), pol
(100 SFC/10 ), and env (100 SFC/10 ) were detected in one infant (B2).
Interestingly, infant B2 presented with the lowest baseline plasma viral load of
the 17 study participants (1700 copies/mL plasma). The difference in the
detection of HIV-1-specific IFN-y responses between the two age groups was
highly significant (Pc:0.005) by Fisher Exact test. Overall baseline IFN-y
ELiSPOT responses were directed against only one HIV-1 gene product in 4/6
infants (67%; infants A5, B 1, B3 , and B4) who generated detectable responses
prior to therapy initiation. The hierarchy of responses among all infants was
nef/pol (n=3) env (n=2) gag (n=1). Background responses to vaccinia were
low in all infants and ranged from 0-60 SFC/10 PBMC (mean: 9 SFC/10
PBMC).
E. HIV-1-specific CD8+ T cell responses following the initiation of antiretroviral
therapy.
To investigate the ability of vertically- infected infants to generate and maintain
responses during combination antiretroviral therapy, the 17 infants were followed
longitudinally through 48 weeks. In both young infants (A5 and A 10) with
Figure 3.
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Figure 2: HIV-1-specific IFN-"f ELiSPOT responses in young infants prior to
and during ART. IFN-7 ELiSPOT responses are shown for all study infants
against wild-type vaccinia virus (NYCBH) (a), HIV- 1 gag (b), HIV-1 pol (c), HIV-
env (d), and HIV-1 nef (e). Virologic responder status is indicated as outlined in
Table I. Asterisks indicate significant responses as defined in Chapter 2. Blank
spaces indicate experiments not performed.
became undetectable following control of viral replication. It should be noted that
both infants were classified as virologic responders and had undetectable plasma
viral loads by 8 weeks following therapy initiation.
Intermittent low-level IFN-y ELiSPOT responses were detected in 6 group A
infants over the course of antiretroviral therapy. Infants A2 , A6 , A7 , A8, A9, and
A 13 generated responses against gag, pol, and nef with a mean of 130 SFC/10
PMBC (range 60 - 240 SFC/10 PBMC). Only one of these infants was classified
as a virologic responder (A13) and 4/6 had detectable plasma HIV-1 RNA at the
time of the positive IFN-y ELiSPOT response.
IFN-y ELiSPOT responses were again detected at subsequent timepoints in
all 4 of the older infants (group B) following therapy. In 3/4 infants (B1, B2 , and
B3) these responses were directed at the same HIV-1 gene products as detected
at baseline. Two of these three infants (B1 and B3) broadened the IFN-
ELiSPOT response to include a second HIV-1 gene product (in both cases, env).
Gag-specific ELiSPOT responses were detected through week 8 in infant B2:
however, pol and env responses were not maintained. Pol responses were not
detected after therapy in infant B4; however an intermittent response to gag was
detected at week 24 of therapy. In 3 of 4 infants, ELiSPOT responses were
detected after the initiation of ART, even following the control of viral replication
(B1 );
F. CD8+ T cells mediate the IFN-y response.
As described above, vigorous IFN-y responses were detected in the baseline
PBMC samples of patients A10 (env and nef) and B2 (gag). CD8+ T cell
depletions were performed to determine which T cell population mediated these
responses. Baseline PBMC samples from both infants were divided into two
fractions, one of which was depleted of CD8+ T cells by magnetic separation.
FACS analysis confirmed that CD8+ T cells represented c:4% of the total small
lymphocyte pool after depletion. The ELiSPOT assay was used to enumerate
IFN-y responses in both the CD8+ and CD8- PBMC fractions for both patients.
Positive responses, against env and nef by infant A10, and against gag by infant
, were again detected only in the CD8+ fractions (data not shown). IFN-
responses were not detected in the CD8- fraction of either infant.
G. Detection of CMV-specific CD8+ T cell responses despite low or absent HIV-
specific responses.
Three young infants (A9, A12 , A13) coinfected with HIV-1 and CMV were
evaluated to determine whether CMV-specific CD8+ T cell responses were
generated prior to and during the course of ART (Fig. 3.3). Recombinant vaccinia
viruses encoding the CMV late gene products pp65 and gB were used with
autologous B-LCL in an ELiSPOT assay. CMV pp65-specific responses were
detected in two infants, A9 and A 13, prior to and during antiretroviral therapy
(range: 100-240 SFC/10 PBMC). Baseline CMV responses in infant A 12 were
not tested; however at weeks 8 and 48 on therapy, pp65-specific (200 and
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Figure 3: Detection of CMV-specific CD8+ T cell responses in three young HIV-
1 and CMV coinfected infants. IFN-7 ELiSPOT responses detected in infants A9,
A12 , and A13 against wild-type vaccinia virus (NYCBH) (a), CMV pp65 (b), and
CMV gB (c). Asterisks indicate significant responses. Blank spaces indicate
experiments not performed.
340 SFC/10 PBMC , respectively) and gB-specific (80 and 60 SFC/10 PBMC,
respectively) responses were detected. Responses to either CMV gene product
were not detected in the PBMC of 2 CMV seronegative infants (data not shown).
H. Discussion.
A modified IFN-y EllS POT , using autologous B-LCL as antigen-presenting
cells , has facilitated the detection and enumeration of low frequency CD8+ T cell-
restricted responses to several HIV-1 gene products. This approach is well suited
for studying CD8+ T cell responses in infants and children since it required only
small numbers of PBMC to evaluate CD8+ T cell-restricted responses to 8 HIV-
gene products. By maintaining a consistent E:T ratio between PBMC and B-LCL
(as well as the infecting MOl), antigen presentation is better standardized when
compared to direct infection of PBMC cultures. Finally, low background
responses by infants to vaccinia and the EBV-transformed B-LCL made this
assay particularly well suited to the study of pediatric samples.
In this chapter, HIV-1-specific CD8+ T cell responses were studied in 17 HIV-
1 vertically- infected infants prior to and during the course of ART. The data
demonstrate that HIV-1 CD8+ T cell responses were less commonly detected in
younger infants (-:6 months of age) than in older infants 
(::
6 months) prior to
ART. Following the initiation of ART , HIV-1-specific CD8+ T cell responses were
uncommonly detected in infants with persistent control of viral replication. Finally,
CMV-specific CD8+ T cell responses were detected in 3 HIV-1/CMV coinfected
infants that lacked HIV-specific CD8+ T cell responses. These results indicate
that young vertically-infected infants can generate and maintain CD8+ T celllFN-
responses, and that host and/or viral factors may specifically impede the
development of early HIV-specific responses in some infants.
CHAPTER IV
Importance of HIV-1 Accessory Gene Products and the Role of Epitope Escape
Mutations in Early Pediatric HIV-1 Infection.
A. Study population characteristics.
Thirteen infants with vertical HIV-1 infection were studied prior to initiation of
combination antiretroviral therapy. All but three infants (P-1042 , P-1043, and P-
1115) were treated with zidovudine, lamivudine, and nevirapine and were
participants in the Pediatric AIDS Clinical Trials Group (PACTG) Protocol 356 , a
clinical trial designed to evaluate the pharmacokinetics of ritonavir in young
infants and the virologic and immunologic consequences of early therapy.
Inclusion in the present study was based solely on PBMC sample availabilty.
Clinical and immune status, viral loads , and response to therapy in our study
population did not differ from the trial group as a whole.
Characteristics of the study population are presented in Table 4. 1. The
median age at study entry was 2.7 mo (range: 1.2-4.8 mo). The median CD4+ T
cell count at study was 2641 celis/ilL (range: 1,370-4 606 celis/ilL). All infants
presented with high levels of HIV- replication (median: 170,672 copies/mL;
range: 16,721- 361,810 copies/mL). PBMC samples drawn prior to the
initiation of therapy were employed in the cross-sectional analysis. PBMC and
plasma samples donated during the course of therapy were also used
Table 4.
Age CD4+ T Plasma HIV- HIV-specific CDS'" T
Patient (mo) cell count RNA cell responses
(celis/uL) (copies/mL)
121 0 2,472 135,417 None detected
1316 3.4 641 97,798 None detected
1327 2,407 128,889 gag, vif
1262 3.4 972 361,810 gag, pol , env, nef, vpr
1217 328 569,813 None detected
1042 640 370,279 gag, nef, tat
1043 681 399,943 rev
1115 370 141 979 gag, pol , env, nef, vpr
1223 606 170,672 env
1244 2.4 085 51,582 QaQ, nef, tat, rev
1247 3,467 16,721 nef
1252 187 217,906 None detected
1235 836 83, 169 None detected
Median 641 170,672
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Table 4.1: Population characteristics at study entry. Age, CD4+ T cell count, HIV-
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1 load, and CD8+ T cell responses are listed for 13 vertically- infected infants.
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for longitudinal analysis of CD8+ T cell responses, viral replication, and viral
sequence analysis in infants P-1042, P-1043, P-1115.
B. HIV-specific CD8+ T cell responses detected in the majority of vertically-
infected infants.
Previous studies by our group and others have found that HIV-specific CD8+
T cell responses are rarely detected in untreated, vertically-infected infants c:6
mo of age (27, 35, 49). It is unclear if the lack of detectable HIV-specific CD8+ T
cell responses is an accurate reflection of the in vivo immune state during
infancy, or if the methodologies employed fail to detect weak or obscure HIV-
specific CD8+ T cell responses.
In the present study, a large panel of recombinant HIV-1 antigens was used
to increase our ability to detect HIV-specific CD8+ T cell IFN-y responses in
young infants prior to the initiation of ART. The new panel added 4 HIV-1 gene
products, the accessory proteins tat, rev, vif, and vpr, to our existing panel of
vaccinia recombinants encoding gag, pol, env, and nef. Aside from the tat and
rev recombinants (based on viral sequence isolated from patient P-1042), all
recombinants were based on either consensus B or common clade B lab strains
(Table 4.2). These vectors were used to infect autologous B-LCL for use as
target cells in an ELiSPOT assay. This approach is not limited by disparities
between patients with respect to HLA class I or antigen processing and
presentation capability. HIV-specific CD8+ T cell responses were detected in 8 of
13 (62%) infants prior to initiation of ART (Figure 4. 1). Among responders, the
HIV-specific CD8+ T cell response was broad (median: 2.5 gene products
recognized), and each HIV-1 gene product in the panel was recognized by at
least one infant. The median frequency of IFN-y-secreting CD8+ T cells among
responders was 270 SFC/10 PBMC (range: 80-5160 SFC/10 PBMC),
consistent with previously reported data from our group and others. No
relationships between the presence of HIV-specific CD8+ T cell responses and
I:'
age , CD4+ T cell count or percentage, or plasma HIV-1 load were observed. j"1Ir'
C. Hierarchy of HIV-specific CD8+ T cell responses and recogniton of HIV-
accessory gene products.
The relative contribution of each HIV-1 gene prodguct in the overall HIV-
specific CD8+ T cell response is ilustrated in Figure 4.2. The hierarchy among
the 22 HIV-specific CD8+ T cell responses detected in the 8 responder infants
was gag, nef (5) env (3) pol , tat , rev, vpr (2) vif (1). Median HIV-specific
CD8+ T cell responses ranged from 140-700 SFC/10 PMBC against single
HIV-1 gene products. Consistent with previous studies in adults and children,
gag-specific CD8+ T cell responses occur most frequently and at the highest
intensity.
Despite the relatively small size of the HIV-1 accessory proteins compared to
the more frequently studied structural proteins, responses against HIV-1 nef, tat
rev, vif, and vpr accounted for over half of the total HIV-specific CD8+ T cell
Table 4.
Vector Gene Product Backaround/Strain
vAbT 141 Qag (p55) Clade B / BH-
vCF21 pol Clade B / HXB2
vAbT 271 env Clade B / BH-
vT23 nef Clade B / NL4.
vT279 tat 1042 isolate
vT320 rev 1042 isolate
vT100 vpr Clade B / IIiB
vT28 vif Clade B / IIiB
Table 4.2: Recombinant vaccinia viruses encoding single HIV-1 gene products.
All vectors courtesy of Therion Biologicals Inc., Cambridge, MA.
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Figure 1: HIV-1-specific CD8+ T cell responses were measured using a
modified ELiSPOT assay in 13 infants prior to initiation of ART. Responses are
recorded as spot-forming cells (SFC) per millon PBMC. Asterisks indicate
responses that met two criteria for positivity: 1. ) duplicate wells must have at
least 60 SFC/10 PBMC, and 2. ) The mean SFC/10 PBMC frequency between
duplicate wells must be greater than 2 times the standard deviation of the mean
background level (vaccinia virus control). Responses against the CMV tegument
protein pp65 are shown in several infants.
response (Figure 4.3). Twelve of 22 responses (55%) were directed against the
accessory gene products. In addition, the intensity of responses directed against
accessory gene products was also considerable - 38% (5380 of 14340 SFC
detected) of the total number of HIV-specific CD8+ T cells detected. Two factors
may have contributed to an underestimation of the accessory gene component of
the HIV-specific response in our study. First, the potent gag-specific CD8+ T cell
response detected in P-1115 accounted for over a third of the total HIV-specific
SFC count (5160 of 14340 total SFC). Indeed, if this response is removed from
consideration, the contribution of responses against nef, tat, rev, vif, and vpr rises
to 59% of the total HIV-specific CD8+ T cell response (5380 of 9180 SFC).
Second, due to the small amounts of PBMC obtained from these infants, vif and
vpr-specific responses were not measured in 3 responder infants (P-1042, P-
1043, and P-1244).
D. Divergent HIV-1 epitope-specific CD8+ T cell responses in infants with similar
HLA haplotypes.
Two infants in the cohort , P-1042 and P-1043, are fraternal twins who appear
to have acquired HIV-1 during delivery. Despite sharing half of their HLA class I
alleles, as shown in Table 4.3, twins P-1042 and P-1043 generated quite
dissimilar HIV-1-specific CD8+ T cell IFN-y responses. Responses against tat
gag, and nef were detected in infant P-1042 whereas a single rev-specific
response was detected in P-1043.
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Figure 4.2: Breadth and intensity of HIV-1-specific CD8+ T celllFN-y responses
in 8 vertically- infected infants. Twenty-two HIV-specific CD8+ T cell responses
were detected against a panel of 8 HIV- 1 gene products. (a) The number of CD8+
T cell responses directed against each HIV-1 gene product by the 8 responder
infants. (b) The median number of HIV-specific CD8+ T cell responses, as
measured by ELiSPOT analysis, directed against each HIV-1 gene product by
the 8 responder infants.
To further investigate these responses, epitope mapping experiments using
the ELiSPOT assay were performed in patient P-1042. Although responses
directed against vectors encoding lab strain HIV-1 antigens were detected in P-
1042 (Le. gag BH-10 and nef NL4.3), the most prominent response was directed
against the vaccinia recombinant vector encoding an autologous tat sequence
isolated shortly after birth. Pools of overlapping peptides spanning the tat protein
and fine mapping using truncated peptides revealed that this early tat-specific
response is focused on a single epitope (tat a.a. 35-44; QACFTTKAL; data not
shown), restricted by the HLA class I Cw 0303 allele. Interestingly, the sequence
of this optimal epitope differs from the more than 35 published clade B isolates
(50). Rather, the majority of isolates contain 3 amino acid differences, including
an A V change at the important 2 a. "anchor" residue. It is unclear whether
these polymorph isms would stimulate the QL9-specific CD8+ T cells in P-1042 , or
if HLA Cw 0303 can bind and present these peptides. This result raises the
possibility that, had not autologous viral sequences been used as the stimulating
antigen, these tat-specific CD8+ T cells would have remained undetected.
E. Longitudinal analyses reveal differential recogniztion of CD8+ T cell epitopes
during early HIV- 1 infection in P-1115.
To examine the development and longevity of HIV-specific CD8+ T cells
during infancy, HIV-specific CD8+ T cell responses were studied in greater detail
Figure 4.
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Figure 4. 3: Contribution of each HIV-1 gene product to the CD8+ T cell response
in 8 responder infants. The number of SFC (per 10 PBMC) detected against
each HIV-1 gene product were totaled and used to compare the intensity of the
CD8+ T cell responses against each HIV-1 gene product. (a) 22 responses
against 8 HIV- 1 gene products. (b). Separate analysis with intense gag-specific
response detected in P-1115 removed from consideration (see text).
in infant P-1115. Longitudinal analysis in this infant was attractive due to the
early and potent HIV-specific CD8+ T cell responses detected prior to the
initiation of ART. ELiSPOT analysis revealed that HIV-specific CD8+ T cell
responses directed at gag, pol , env , were maintained during the first year of life,
despite significant decreases in plasma viral loads concurrent with ART initiation
(Figure 4.4). Since this infant expresses the common HLA class I A *02 allele,
longitudinal PBMC samples were stained with HLA class I tetramers specific for
the immunodominant SL9 epitope found in gagp17 (Figure 4.5). Interestingly, SL9-
specific CD8+ T cells were not detected until the second year of life in the PBMC
of infant P-1115, suggesting that an alternative gag epitope (or epitopes)
mediated the early gag-specific CD8+ T cell response.
To identify the epitope(s) targeted during the early gag-specific CD8+ T cell
response in P-1115, pools of overlapping peptides spanning the gag protein were
used in an ELiSPOT analysis (Figure 4.5). PBMC drawn 6 weeks following
therapy initiation revealed a highly focused response directed at peptide #91 , a
peptide spanning the p24/p2 cleavage site within gag. Fine mapping using
truncated peptides revealed that the response was directed at the previously
identified W9 epitope (VLAEAMSQV), restricted by HLA A*02 (data not shown).
Confirming the HLA tetramer analysis, a SL9-specific CD8+ T cell response was
detected in PBMC drawn 77 weeks following therapy initiation. These data
indicate that a significant shift in epitope dominance and usage occurred during
the end of the first year of life in infant P-1115. Early CD8+ T cell responses
Table 4.
Patient HLAA HLAB HLAC
1042 1101; 2602 3901; 5101 0303; 1203
1043 A* 2602; 3002 1801; 3901 0501; 1203
Table 4.3: Class I HLA genotype for twins P-1042 and P-1043. Shared alleles
are in bold.
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Figure 4: Longitudinal HIV-specific CD8+ T cell responses in infant P- 1115. (a)
The ELiSPOT assay reveals strong gag-specific CD8+ T cell IFN-g responses
during the first year on therapy. (b) A classically-defined A *0201-restricted CD8+
T cell response against the gag SL9 epitope is absent during the first year of life,
but quickly develops into the dominant gag-specific CD8 + T cell response.
targeted only the gag W9 epitope during the first year of life. Thereafter, the SL9
epitope was the predominant target of the gag-specific CD8+ T cell response.
F. Role of viral escape mutations during early pediatric HIV-1 infection.
One potential explanation for the absence of SL9-specific CD8+ T cells during
the first year of life in infant P-1115 is the presence of escape mutations within
CD8+ T cell epitopes. It is possible that escape mutations could have been
transmitted to the infant from its mother, who shares at least half of her HLA
class I allotype with P-1115. To test this hypothesis, viral sequences spanning
the SL9 epitope within the gag gene were obtained at 4 timepoints that span the
first two years of ART administration in patient P-1115. As presented in Table
4.4, viral sequence analysis of the SL9 epitope failed to reveal any deviation from
the "wild-type" SL YNTV A TL epitope. Given the lack of non-synonymous
mutations within the SL9 epitope, it appears unlikely that the absence of SL9-
specific CD8+ T cell responses during the first year of life can be attributed to an
epitope escape mechanism. Interestingly, wild-type sequences persisted even
following the generation of a potent gag SL9-specific CD8+ T cell response
suggesting either that the detected CD8+ T cell responses did not exert immune
pressure on the SL9 epitope or that sequence variation within this epitope may
impair viral fitness.
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Figure 5: Overlapping gag peptides (15 a. ) were pooled (A-V) and used to
map HIV-specific CD8+ T cell responses in infant P- 1115. (a) At week 6 of
therapy, the gag-specific response is tightly focused on the A *020 1-restricted
VV9 epitope at the p24/p2 junction (peptide 91). (b) Conversely, by week 77 on
therapy, the gag-specific response has dramatically shifted to the A *0201-
restricted SL9 epitope in p17 (peptides 19 and 20). TNTC = too numerous to
count.
Table 4.
Study Week Age (mo) Sequence Frequency
SL YNTVATL 11/11
SL YNTV A TL 10/10
SL YNTV A TL 4/4
150 SL YNTVATL 6/6
Table 4.4: Sequence analysis of the SL9 gag CD8+ T cell epitope from infant P-
1115 reveals no deviation from the common SL YNTV A TL epitope motif, despite
a marked shift in CD8+ T cell epitope usage during this period.
G. Discussion.
In this chapter, HIV-1-specific CD8+ T cell responses were detected in 8 of 13
infants 0:6 mo of age, prior to initiation of ART. Responses against HIV-1 gag and
nef were most commonly detected , but a significant portion of detectable
responses were directed at other HIV-1 accessory proteins (tat , rev, vif, and vpr).
These data suggest that the accessory proteins commonly serve as targets in the
overall HIV-specific CD8+ T cell response during early vertical infection. 1 i 
The disparate tat and rev-specific responses generated by infants P-1042 and
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CHAPTER V
HIV-1 Replication Increases HIV-Specific CD4+ T Cell Frequencies but Limits
Proliferative Capacity in Chronically- Infected Children.
A. Study population characteristics.
Peripheral whole blood samples were acquired from 44 children with
established HIV-1 infection. Characteristics of the study cohort are presented in
Table 5. 1. Study children were placed into groups based on plasma HIV-1 load
and ART history. Children in group A (n=16) were on combination ART and had
plasma HIV-1 RNA 0:50 copies/mL. Children in group B (n=22) were also on
combination ART but had plasma HIV- 1 RNA 50 copies/mL (median: 1316
copies/mL; range: 99-57901 copies/mL). Age at study entry, median CD4+ T
cell counts, and median duration of ART prior to study enrollment did not differ
significantly between these two groups. Several children (group C, n=6) were
either not receiving ART or were not adherent to a prescribed therapy (median
plasma HIV-1 RNA: 60603 copies/mL; range: 11427-259350 copies/mL).
Finally, 10 HIV-uninfected adults (group D) served as negative control donors.
B. HIV-1 gag p55-specific CD4+ T cells are commonly detected in children with
established HIV-1 infection.
Table 5.
Group Patient Age CMV %CD4 CD4+ T cell Plasma Antiretroviral Therapy Time on
(y)
Status count HIV-1 RNA Therapy
cells (cells/J.L) (copies/mL
(y)
1006 18. 801 0:50 ddl, EFZ, NFV
n=16 1025 12. 730 0:50 d4T, RTV
1033 N/A 713 0:50 ddl, d4T, RTV , VPT
1035 375 0:50 ddl , d4T, IDV, RTV
1040 961 0:50 d4T, 3TC, BMS
1111 12. 1339 0:50 d4T , 3TC, NVP
1112 11. 552 0:50 ddl , NFV, SQV
1115 1040 0:50 3TC, ZDV, NFV
1116 N/A 0:50 3TC, ZDV
1118 N/A 0:50 3TC, ZDV, NFV
1119 1490 0:50 ddl , NVP , NFV
1207 10.4 1404 0:50 ddl , d4T, RTV 1.4
1209 1039 0:50 d4T, 3TC, NVP, NFV
1211 1710 0:50 d4T , 3TC, NVP , NFV
1318 1043 0:50 d4T, 3TC, NVP , NFV
1322 11. 1612 0:50 d4T , 3TC, RTV, SQV
Median 1040 0:50
1008 16. 438 1846 d4T, 3TC, EFZ, AMP 1.4
n=22 1011 15. 504 7445 3TC, ZDV , NFV 5.4
1012 15. 538 601 ddl, d4T
1014 15. 524 2102 d4T , 3TC, NFV
1020 12. 855 407 3TC. ZDV
1022 12. 556 ddl, EFZ
1023 12. 752 57901 d4T, 3TC, LOP/RTV 1.4
1030 109 600 3TC, TNV , EFZ
1031 488 5302 ddl , TNV, EFZ, LOP/RTV
1036 911 499 ddl , d4T, NFV, RTV
1037 572 964 d4T, 3TC, NVP
1039 996 953 d4T
1044 1211 2817 ddl, d4T
1045 1571 680 AZT, ddl , RTV
1047 1223 3334 d4T , 3TC, NFV
1110 12. N/A 134 ddl, d4T, NVP
1117 1632 665 d4T, NVP, NFV
1201 15. 505 285 ddl , KAL, TNV
1210 N/A 2489 d4T , 3TC, NFV
1319 976 43470 d4T , 3TC, NVP , NFV 1.4
1320 1209 24514 d4T, 3TC, NFV
1326 458 1667 AZT, 3TC, NVP , NFV
Median 662 1316
1017 13. 122 100085 No therapy
n=6 1046 736 259350 ZDV , 3TC, BMS
1107 13. 502 11427 No therapy
1120 N/A 951 21121 AZT, ddl, D4T, NVP, NFV
1199 17. 299 13867 d4T , 3TC, BMS
1325 138 125755 No thera
Median 10. 401 60603
Table 5. 1: Study population characteristics.
Using an intracellular cytokine staining assay (ICS; Figure 5. 1), HIV-1 p55-
specific CD4+ T cell responses were detected in 38 (86%) of 44 study children at
a median frequency of 0.34% (range: 0.02- 88%) of CD4+/CD45RO+ small
lymphocytes. No relationships between age, CD4+ T cell percentage or count
and the detection or frequency of p55-specific CD4+ T cell responses were noted.
To confirm the HIV- specificity of the detectable CD4+ T cell IFN-y
responses, blood samples from 10 HIV-1-uninfected adult donors were tested
(group D). HIV-1 p55-specific CD4+ T celllFN-y responses were not detected in
the peripheral blood samples of any individuals in this group.
C. HIV- 1 gag p55-specific CD4+ T cells are detected more commonly and at
higher frequencies in children with ongoing HIV-1 replication.
Interestingly, 5 of the 6 children without detectable HIV-1 p55-specific CD4+ T
cell responses also had plasma HIV-1 RNA -:50 copies/mL. We therefore went
on to examine the relationship between plasma HIV-1 load and HIV-1 p55-
specific CD4+ T cells. HIV-1 p55-specific CD4+ T cell responses were less
commonly detected in children with plasma HIV-1 RNA -:50 copies/mL than in
children with ongoing replication (Table 5.2). HIV-1 p55-specific CD4+ T cell
responses were detected in 11 (69%) of 16 children with undetectable HIV-
plasma loads while HIV-1 p55-specific CD4+ T cell responses were detected 
27 (96%) of 28 children with plasma HIV- 1 RNA 50 copies/mL. In addition
higher frequencies of HIV-1 p55-specific CD4+ T cells were detected in children
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Figure 1: Detection of ex vivo HIV-1 gag p55-specific and CMV pp65-specific
CD4+ T cell IFN-y responses by intracellular cytokine staining. Shown is a
representative flow cytometry profile of a child with detectable IFN-y responses
against both HIV-1 p55 and CMV pp65 protein antigens. After gating on small
lymphocytes, CD4+/CD45RO+ double positive cells were analyzed for co-
expression of IFN-y and the activation marker CD69.
Table 5.
HIV-1 Re lication Status
0:50 copies/m L
50 copies/m L
p-value (Fisher s Exact Test)
Table 5.2: Forty four children infected with HIV-1 were analyzed for the presence
of HIV-1 and CMV-specific CD4+ T cell IFN-y responses. The proportion of
children with plasma HIV- 1 loads c:50 copies/mL (undetectable; group A) or 
copies/mL (groups B and C) with positive CD4+ T cells responses against HIV-
p55 and CMV pp65 antigens are listed. Only children co- infected with CMV were
considered in the analysis of CMV-specific responses. CMV-specific responses
were not studied in all co- infected children due to insufficient specimen samples.
with active viral replication than in children with suppressed viral replication. As
shown in Figure 5.2A, HIV-1 p55-specific CD4+ T cell responses were detected
at higher frequencies in group B (median: 0.57%; range: 0.08- 80%) and in
group C (median: 0.30%; range: 0.04- 88%) than in group A (median: 0. 14%;
range: 0.02- 7%). While the difference in HIV- p55-specific CD4+ T cell
frequencies between group A and group B was statistically significant (Wilcoxon
Rank Sum: p=0.004), the difference in HIV- p55-specific CD4+ T cell
frequencies between groups A and C was not statistically significant. The latter
may be due to alteration of the relationship between viral replication and CD4+ T
celllFN-y responses by CD4+ T cell depletion, as discussed below.
D. Cross-clade stimulation of HIV-1 gag p55-specific CD4+ T cell responses.
The use of a clade B-derived (SF2 isolate) p55 protein antigen raised the
concern that HIV-1 p55-specific CD4+ T cell responses may not be detected in
children infected with other HIV-1 subspecies. Five children were born to women
who acquired HIV-1 in areas in which non-clade B viruses predominate (P-1209
and P-1326 , Zimbabwe; P-1210, South Africa; P-1211 , Cambodia; P-1318, Ivory
Coast). Responses were detected in 2 children (P-1210 and P-1326), born to
mothers most likely infected with HIV-1 clade C viruses. Importantly, both
responders had detectable plasma HIV-1 RNA, whereas each of 3 children
lacking detectable p55-specific CD4+ T cell responses presented with plasma
HIV-1 RNA c:50 copies/mL.
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;. +.. . .........,......... ........... .....
n=16 n=22 n=6 n=10
ag 1.
:: 2.
;; 1.
() 0.
p=O. 004 
p=O. 028 
. ............  
''0'"
'''''' ''''
n=5 n=10 n=4
Patient Group
n=2
Figure 2: Frequency of ex vivo (a) HIV- 1 gag p55-specific and (b) CMV pp65-
specific CD4+ T cell IFN-y responses in HIV-1 chronically-infected children. The
percentage of CD4+/CD45RO+ small lymphocytes that produce IFN-y and
express CD69 in response to specific viral antigen stimulation is shown by
patient group, as described in Table II (children with 0:15% CD4+ T cells (0);
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E. CMV pp65-specific CD4+ T cells are detected at higher frequencies in children
with "'50 copies/mL plasma HIV- 1Ioad.
To further our understanding of virus-specific CD4+ T cells in HIV-infected
children, CMV tegument pp65-specific CD4+ T cell frequencies were also
measured in 19 HIV-1 and CMV co-infected children. CMV pp65-specific CD4+ T
cell IFN-y responses were detected in 13 (68%) of 19 children at a median
frequency of 0. 18% (range: 0-4.37%). As presented in Table 5.2, CMV-specific
CD4 + T cell responses were detected more frequently in children with plasma
HIV-1 RNA "'50 copies/mL (5/5 , 100%) than in those children with active HIV-
replication (8/14, 57%). The difference in proportion of responders did not reach
statistical significance, but suggested a trend towards an inverse relationship
between active HIV-1 replication and the presence of CMV-specific CD4+ T cell
responses. To further investigate this relationship, the frequencies of CMV pp65-
specific CD4+ T cell IFN-y responses were plotted by group. As ilustrated in
Figure 5. , all 5 children in group A had detectable pp65-specific CD4+ T cell
responses at a median frequency of 1.07% (range: 0.1-4.37%). Conversely,
only 5 (50%) of 10 children in group B had detectable pp65-specific CD4+ T cell
IFN-y responses (median: 0.07% range: 0- 68%). These responses were
significantly lower than those detected in group A (Wilcoxon Rank Sum:
p=0.028). CMV pp65-specific CD4+ T cell IFN-y responses were detected in 3
(75%) of 4 children in group C at intensities similar to those found in group 
(median: 0.016%, range: 0.03- 25%).
To confirm the specificity of the detectable CD4+ T cell IFN-y responses,
blood samples from 2 HIV-1 and CMV-uninfected adult donors were tested
(group D). No CMV pp65-specific CD4+ T cellIFN-y responses were detected in
these individuals.
F. Low frequency virus-specific CD4+ T cell IFN-y responses in children with
depleted CD4+ T cells.
CD4+ T cell percentages of c:15% are associated with higher mortality in HIV-
infected children (51). Within the cohort, only 2 patients in group C, P- 017 and
1325, presented with severely depressed CD4+ T cell percentages (c:15%) and
counts (c:150 celis/f.L). Despite high-level viremia in both children (
copies/mL), HIV-1 p55-specific CD4+ T cell IFN-y responses (Figure 5.2A, open
circles) were either undetectable (P-1017) or low frequency (P-1325; 0.04%).
Similarly, CMV-specific IFN-y responses (Figure 5.B, open circles) were either
undetectable (P-1325) or low frequency (P-1017; 0.08%). These data suggest
that CD4+ T cell depletion may alter the previously observed relationship
between plasma HIV-1 load and the intensity of p55-specific CD4+ T cell IFN-y
responses.
G. Ongoing HIV-1 replication is associated with detectable HIV-specific CD4+ T
cell responses.
Despite undetectable HIV-1 viral loads, some variability was observed in HIV-
1 p55-specific CD4+ T celllFN-y responses in group A. HIV-1 2- TR DNA circles
were measured in the PBMC obtained from 14 children in group A at the same
timepoints used in the ICS data presented above. Limited PBMC sample
volumes precluded further study of the remaining 2 children (P-1033 and P-
1035). Two- TR DNA circles are abortive products of HIV-1 reverse transcription
that occur when proviral DNA fails to integrate into the host genome (52). The
presence of 2- TR DNA circles within peripheral blood lymphocytes represents
ongoing HIV-1 replication. Nine children in whom HIV-1 p55-specific CD4+ T cell
IFN-y responses (median frequency: 0.22%; range: 0.09- 70%) were detected
were defined as "responders," As ilustrated in Figure 5.3, HIV-1 2- TR DNA
circles were detected in all 9 responder children, at a median frequency of 3.
copies/10 PBMC. By contrast, 2-L TR DNA circles were detected at a frequency
of 0:1 copy/10 PBMC in all 5 non-responder children. The difference in the
median frequencies of 2-L TR DNA circles between the two groups proved to be
significant (Wilcoxon Rank Sum: p=0.04).
H. Changes in HIV-1 gag p55-specific CD4+ T cell frequencies are temporally
associated with changes in plasma HIV-1Ioad.
Since our data suggested an association between HIV-1 replication and HIV-
p55-specific CD4+ T cell IFN-y responses, follow-up ICS assays were
performed in several children who returned to the clinics. In most cases, plasma
Figure 5.
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Figure 5.3: HIV-1 2- TR DNA circle copy numbers in children with plasma HIV-
RNA c:50 copies/mL and detectable ("responders ) or undetectable ("non-
responders ) HIV-1 gag p55-specific IFN-y responses.
HIV RNA loads and HIV-1 p55-specific CD4+ T cell frequencies were stable over
time (data not shown). However, changes in plasma HIV-1 RNA levels were
accompanied by changes in p55-specific CD4+ T cell frequencies (Figure 5.4).
For example, patient P-1320 presented with plasma HIV-1 RNA of 24,514
copies/mL and an HIV-1 p55-specific CD4+ T cell IFN-y response of 1.80%
(Figure 5.4a). Following a change in therapy and a reduction of viral load by over
1 log, the p55-specific CD4+ T cell frequency fell to 0.57%. Conversely, child P-
1207 presented with plasma HIV-1 RNA 0:50 copies/mL plasma HIV-110ad and a
weak HIV-1 p55-specific CD4+ T celllFN-y response (0.09%; Figure 5.4b). Over
the course of two months, HIV-1 RNA became detectable in this child's plasma
(-1100 copies/mL at two timepoints) and the frequency of HIV-1 p55-specific
CD4+ T cell responses rose to 0.90%. The temporal association between plasma
HIV-1 load and the frequency of p55-specific CD4+ T celllFN-y responses again
ilustrates the dependency of HIV-specific CD4+ T cell responses on the
availabilty of HIV-1 antigen.
I. Diminished HIV-specific in vitro Iymphoproliferative responses in children with
active HIV-1 viral replication.
Nineteen children studied using the ICS assay (8 in group A, 9 in group B, 2
in group C) were concurrently tested for the presence of Iymphoproliferative
responses (LPA) against HIV-1 p55 (Figure 5.5); HIV- p55-specific IFN-
secretion was detected in 16 (84%) of these 19 children. By contrast, HIV-1 p55-
specific Iymphoproliferative responses were detected in only 6 of 19 (32%)
children tested. LPA responses were detected in 4 of 8 (50%) children with c:50
copies/mL plasma HIV-1 load (group A), but were detected in only 2 children (P-
1012 in group Band P-1107 in group C) with plasma HIV- 1 RNA 50 copies/mL.
CD4+ T cell counts were similar in both groups, suggesting that the observed
differences in HIV-1 p55-specific LPA responses were due to differences in viral
load. HIV-1 p55-specific LPA responses were not detected in 6 HIV-uninfected
donors (group D). Interestingly, there was no apparent relationship between the
presence of p55-specific LPA responses and the frequency of CD4+ T celllFN-
responses (data not shown), although concurrent p55-specific CD4+ T celllFN-
responses (responder median: 0.68%; range: 0.13- 86%). were detected in 5
of the 6 (83%) LPA responders. HIV-1 p55-specific CD4+ T celllFN-y responses
were also detected in 11 of 13 (85%) LPA non-responders.
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. Figure 5.4: Temporal association of changes in HIV-1 gag p55-specific CD4+ T
cell IFN-y responses in children with changes in plasma HIV-1 RNA levels.
Plasma HIV-1 load (0) and HIV-1 gag p55-specific CD4+ T celllFN-y frequencies
(8) are plotted for patients P-1320 and P1207.
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Figure 5.5: HIV-1 gag p55-specific CD4+ T cell in vitro proliferation in children
with suppressed or active HIV-1 replication. Stimulation indices greater than 3
were considered positive.
J. Discussion.
Data from the present study demonstrate that ex vivo HIV-1 and CMV-specific
CD4+ T celllFN-y responses are commonly detected in children with established
HIV-1 infection, despite the diverse therapeutic, clinical, and virological
backgrounds of these children. Responses were more commonly detected and
were detected at higher frequencies in the circulation of children with plasma
HIV-1 RNA ::50 copies/mL than in children with plasma HIV-1 RNA 0:50
copies/mL. Conversely, CMV pp65-specific CD4+ T cell IFN-y responses were
more commonly detected and were detected at higher frequencies in children
:1:
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with undetectable plasma HIV-1 load. These data suggest that CD4+ T celllFN-
responses can be primed and maintained in vertically-infected children.
Furthermore, the detection of HIV-specific CD4+ T cells in most children, at
;j:
frequencies comparable to those found in adults, indicates that the generation
I ,
and maintenance of these cells are not appreciably altered by long-standing HIV-
replication. However, the weak or undetectable HIV-1-specific CD4+ T cell
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responses detected in 2 children with severely depleted CD4+ T cell percentages
III
suggests the importance of immune competence in maintaining these responses 11J
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over time. Our findings are compatible with studies in chronically-infected adults 1111
that demonstrate that HIV-1 and other virus-specific CD4+ T cells are not deleted
following prolonged viremia (41 , 42 , 44, 45).
In children with plasma HIV-1 RNA 0:50 copies/mL, HIV-1 p55-specific CD4+ T
cell IFN-y responses were detected only in the peripheral blood of children in
whom 2-L TR DNA circles were detected using a real-time PCR-based assay.
While some groups have questioned the validity of 2- TR circles as a marker of
ongoing viral replication (53, 54), the correlation between the detection of HIV-
p55-specific CD4+ T celllFN-y responses and the presence of 2- TR DNA circles
underscores their utilty as a surrogate of covert viral replication. These data
ilustrate the abilty of ongoing HIV- replication to drive and maintain HIV-
specific CD4+ T cell IFN-y responses, and that low-level HIV- replication,
undetectable by ultrasensitive quantitation assays, is sufficient to maintain HIV-
specific CD4+ T cell frequencies comparable to those ' found in children with
significantly higher viral burdens.
Chapter VI
Discussion
A. Thesis Overview
A better understanding of the relationship between HIV-1 replication and HIV-
specific immunity in vertically- infected infants and children is necessary for the
successful development of effective treatment strategies, including a protective
HIV-1 vaccine. Experimental data presented in this thesis dissertation examined
the frequency, specificity, and timing of pediatric T cell responses against HIV-
As ilustrated in chapter 3, HIV-1-specific CD8+ T cell responses were less
commonly detected in younger infants (c:6 months) than in older infants (
months) prior to ART. Following the initiation of ART, HIV-1-specific CD8+ T cell
responses were uncommonly detected in infants with persistent control of viral
replication. The detection of CMV-specific CD8+ T cell responses in young HIV-
1/CMV coinfected infants indicates that young infants are capable of generating
and maintaining CD8+ T cell response directed against a vertically-acquired viral
infection.
In chapter 4, HIV-specific CD8+ T cell responses were detected more
frequently using an expanded panel of HIV-1 antigens. CD8+ T cell IFN-
responses against HIV-1 accessory gene products represented nearly half of
detectable responses. This finding suggests that inclusion of HIV-1 accessory
gene products into vaccine strategies may improve immunogenicity and efficacy.
A detailed analysis of early HIV-specific CD8+ T cell responses in a pair 
fraternal twins underlines the challenges to generating broad and intense CD8+ T
cell responses in a diverse population. Finally, the potent gag-specific CD8+ T
cell response in a young infant is characterized. Despite strong gag-specific
CD8+ T cell responses during the first 2 years of life, a marked shift in gag
epitope usage is observed. Viral sequence analysis revealed that epitope
escape, or the evolution of viral species with sequence mutation that would
inhibit CD8+ T cell recognition, does not mediate the epitope shift observed in this
infant.
Finally, in chapter 5, HIV-specific CD4+ T cell IFN-y responses were
commonly detected in a large cohort of children with established HIV-1 infection.
A close relationship between the presence and frequency of HIV-specific CD4+ T
cells and plasma HIV-1 load was observed. The majority of children with active
HIV-1 replication failed to mount appreciable HIV-specific proliferative responses,
despite displaying high frequencies of IFN-y producing cells. These data support
the uninterrupted use of combination ART in HIV- infected children to preserve
HIV-1 and other virus-specific CD4+ T cell function by controllng HIV-
replication. Vaccination to stimulate HIV-specific CD4+ T cell responses under
continued ART may improve the long-term control of viral replication, and
perhaps allow the eventual discontinuation of ART.
B. Rationale for the study of pediatric HIV-specific T cell immunity.
Antiretroviral therapy (ART) has proven to be an important tool in the
prevention of mother-to-child transmission of HIV-1 infection , but it is clear that a
long-term prevention and treatment strategy can not rely on ART alone. Early
treatment of HIV- infected infants with ART effectively reduces HIV-1 replication
and has dramatically improved the long-term prognosis for infants and children
living with HIV-1. Single or short-course ART may hold promise in regions of the
developing world , but the expense and expertise required to dispense this care
has limited its impact. Even with reduced perinatal transmission rates, current
ART interventions do not appear to provide protection against HIV-1 transmission /11
Iii
ii;
I:!through breastmilk. Finally, the lack of HIV-1 antigens for presentation to HIV-
specific CD8+ T cells in treated infants and children may not allow eventual
cessation of antiretroviral therapy. A neonatal vaccine to boost HIV-specific
cellular immune responses in infants may provide protective immunity to HIV- ;:1
or at least reduce HIV-1 viral burden and delay immunodeficiency disease iil
progression. A better understanding of HIV-specific CD8+ and CD4+ T cell IiI
responses in infants and children is vital to the development of an effective
pediatric vaccine.
iii
C. HIV-specifc CD8+ T cell responses during infancy.
Data from adult human (21 , 55, 56) and simian (31, 32) studies have
demonstrated the importance of the HIV-1-specific CD8+ T cell response in
controllng primary HIV-1 viremia. The expansion of HIV-1-specific CD8+ T cell
populations during the acute phase of infection is thought to contribute to the
establishment of an equilibrium between viral replication and the host immune
system (viral setpoint) that is predictive of subsequent disease progression. HIV-
1-specific CD8+ T cells also appear to playa critical role in the control of viral
replication during the course of chronic infection (57).
While much effort has been made to characterize the breadth, intensity, and
timing of HIV-1-specific CD8+ T cell responses in infected adults, the generation
and maintenance of HIV-1-specific CD8+ T cells in vertically-infected infants are
less well understood. A general paucity of PBMC samples and infrequent
detection of antigen-specific CD8+ T cells has made study of HIV-1-specific CD8+
cell responses difficult in young infants. Responses to reported
immunodominant epitopes commonly recognized by adults with established
infection (58) are rarely detected in young infants (our unpublished data). This
may indicate differential recognition of HIV-1 epitopes over the course of infection
(59) or that different HIV-1 peptide epitopes are preferentially recognized by
young infants.
In chapter 3, the difference in detectable HIV-1-specific CD8+ T cell
responses between infants of the two age groups prior to therapy was highly
significant and may reflect age-related differences in the dynamics of activation
and expansion of antigen-specific CD8+ T cells in young infants. In this regard, it
is interesting to note that the infrequent detection of HIV-1-specific CD8+ T cell
responses in young infants prior to ART contrasts with the frequent detection of
HIV-1-specific CD8+ T cell responses prior to therapy in adults with primary HIV-
infection (33). HIV-1-specific CD8+ T cell responses were lower in frequency and
less broad in adults who initiated ART within 6 months of infection than in
individuals who initiated ART 6 months following infection, suggesting that a
reduction in viral replication during primary infection decreases the frequency and
breadth of HIV-1-specific CD8+ T cell responses. However, HIV-1-specific CD8+
T cell responses were persistently detected in the majority of adults at least one
year following the initiation of potent combination ART.
The more frequent detection of HIV-specific CD8+ T cell responses (in 8 of 13
infants presented in chapter 4) stands in contrast to the data presented in
chapter 3. Remarkably, the infants in both cohorts were quite similar with respect
to age , standard of care, HIV-1 replication , and CD4+ T cell counts. Moreover
the methodology used to detect responses (B-LCL/ELISPOT) was identical
between studies, aside from the inclusion of recombinant tat, rev, vif, and vpr
antigens. Considering the contribution of CD8+ T cell responses specific for the
HIV-1 accessory gene products to the overall anti-HIV response in the current
study, the experimental results presented in chapter 3 most likely underestimated
the level of HIV-specific CD8+ T cell immunity present in the young infants.
Interestingly, HIV-specific CD8+ T cell responses were only detected in 10 of
26 infants c:6 mo of age if the results of both chapters are combined. Several
unique characteristics of the neonatal cellular immune system and the dynamics
of vertical HIV-1 infection may help to explain the infrequent detection of CD8+ T
cell responses to HIV- 1. First, the cellular immune system in neonates and young
infants may have different requirements for the activation and expansion of
antigen-specific CD8+ T cells. The antigen-processing and presentation capabilty
of infant antigen presenting cells has been questioned, especially with regard to
dendritic cell function (60). Inefficient presentation of HIV-1 antigens to na'ive
CD8+ T cells may hinder the generation of effector and memory CD8+ T cell
populations. Second, Selin et al. have demonstrated that sequential viral
infections shape the memory T cell pool through the expansion or deletion of
cross-reactive CD8+ T cell populations (61, 62). Limited exposure to
heterologous viruses during the first months of life may impair the generation and
expansion of CD8+ T cell populations cross-reactive with HIV-
The detection of CMV-specific CD8+ T cells in 5 young HIV-1/CMV-coinfected
infants (again, combining results of chapters 3 and 4) suggests that young infants
are capable of generating virus-specific CD8+ T cell responses. CMV-specific
responses were detected at all timepoints studied in 5 young coinfected infants,
at frequencies similar to those detected in CMV seropositive , HIV-1-uninfected
adults (unpublished data). Initiation of ART did not appear to alter CMV-specific
CD8+ T cell frequencies over time. The detection of CMV-specific CD8+ T cells in
3 young HIV-1/CMV-coinfected infants suggests that young infants are capable
of generating virus-specific CD8+ T cell responses and that the paucity of
detectable HIV-1-specific CD8+ T cell responses represents a selective defect in
the generation or maintenance of HIV-1-specific CD8+ T cells.
There are several potential explanations for the apparent selective defect in
the generation or maintenance of HIV-1-specific CD8+ T cells in these young
infants. First, murine models suggest that the development of neonatal CD8+ T
cell responses is highly influenced by antigen load and the antigen presenting
cell (63 , 64). Differences in the kinetics and sites of HIV-1 and CMV replication
may therefore lead to differential generation or maintenance of cellular immune
responses directed against these viruses in coinfected hosts. Second , the
acquisition of HIV-1 infection in the presence of high titers of passively-acquired
maternal antibodies may also affect the generation of HIV-1-specific CD8+ T cell
responses. The deletion of HIV-1-specific CD4+ T cells by the cytopathic effects
of HIV-1 may contribute to the low frequency of HIV-1-specific CD8+ T cells. HIV-
1-specific CD4+ T cell responses appear to be important for the generation and
maintenance of potent HIV-1-specific CD8+ T cell responses (34, 39). For
instance , several HLA class I alleles have been shown to correlate with more
rapid HIV-1 progression, implying these alleles do not mediate numerous or
potent HIV-specific CD8+ T cell responses (65). Viral polymorph isms or escape
mutations passed on from the mother may inhibit the generation of detectable
CD8+ T cell responses in the infant (66). Finally, the use of IFN-y as the readout
for antigen specificity may underestimate or completely miss populations of HIV-
1-specific CD8+ T cells with alternate effector phenotypes.
D. Importance of HIV- 1 accessory proteins in the CD8+ T cell response.
Although several CD8+ T cell epitopes have been identified within HIV-
accessory proteins , they are few in number compared to those identified within
the larger, canonical proteins gag, pol, and env. While it is tempting to conclude
that HIV- accessory proteins are preferentially targeted during pediatric
infection, it is more likely that the methodologies and reagents used in previous
studies did not faciltate detection of accessory gene-specific responses. To
illustrate, many investigators examining CD8+ T cell responses in adults (and
infants/children) tend to focus on responses directed against epitopes within gag,
pol, and env, largely because these antigens (peptides, whole proteins,
recombinant vectors) are more readily available for experimental use.
Additionally, many studies have relied heavily on HLA class I tetramers against
immunodominant" epitopes, found primarily within gag, to gauge the overall
CD8+ T cell immune response against HIV-1. Reliance on HLA class I tetramers,
typically manufactured using a limited set of class I A or B alleles, does not allow
for a complete evaluation of all antigen-specific CD8+ T cells that may be
present.
E. Role of HLA and viral sequence in shaping early CD8+ T cell responses.
The strikingly distinct CD8+ T cell responses detected in fraternal twins P-
1042 and P-1042 underlines the challenges faced in selecting HIV-1 antigens
appropriate for incorporation into a pediatric vaccine. The tat and rev-specific
CD8+ T cell IFN- responses generated by twins P-1042 and P-1043,
respectively, were in the context of relatively obscure HLA class C alleles. Since
the binding characteristics of many C loci remain unknown , currently available
epitope prediction softare tends to skew epitope mapping studies towards the A
and B class I loci. Clearly, HLA class I genotype plays an important role in
mediating the CD8+ T cell response , but uncommon viral polymorph isms within
infected infants and children also make prediction and identification of CD8+ T
cell epitopes difficult. The sequence of the novel tat-specific CD8+ T cell epitope
recognized by P-1042 (restricted by HLA Cw 0303) is unique among published
sequences in the Los Alamos Sequence Database (50). The use of HIV-
antigens based on common lab strain clade B isolates may have failed to detect
this tat-specific response. The parallel is clear-vaccine strategies based on
consensus or lab-adapted isolates may fail to provide protective immunity.
F. CD8+ T cell responses and viral escape in HIV-infected infants.
Escape mutations within HIV-1 and SIV (in animal models) CD8+ T cell
epitopes have been characterized in several studies (67, 68). The high error rate
of the HIV-1 RT enzyme allows for the generation of viral variants that, in the
face of selective pressures, generate non-synonymous base pair mutations
within regions of the viral genome that benefit overall replicative "fitness." We
hypothesized that the absence of SL9-specific CD8+ T cells during the first year
of life in infant P-1115 was due to the transmission and outgrowth of viral species
containing escape mutations within the SL9 epitope. One study has documented
the transmission of such immune escape mutations in human vertical HIV-
infection , but the conserved nature of the SL9 epitope may not make it an
attractive epitope for continued studies of transmittable mutations (66).
Interestingly, Goulder et al. have also described a group of HLA A*02 adults
during acute and chronic HIV-1 infection with very similar shifts in epitope usage
(59). Despite the frequent detection of gag SL9-specific CD8+ T cell responses in
chronically-infected HLA A *02+ adults, no such responses or cell populations
were detected in 11 adults during acute infection. Gag SL9-specific CD8+ T cells
later became detectable in 2 subjects that were followed longitudinally.
MI:i
I!II;II
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Additionally, analysis of viral sequences during acute viremia did not reveal
i:!liil
MIl!
illl,
substantial deviations from the standard SL YNTVATL sequence. The striking
!Jlli:
III!
iill!il
similarity of the late emergence of SL9-specific CD8+ T cells in the absence of 'II
III1111
illustrates a common pattern for the establishment of CD8+ T cell dominance.
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viral escape variants between these adults and infant P-1115 (in our study)
This pattern appears to be unaffected by differences in age, and closely related
IllfI:1
11111:
illll'
Illlli'
li1i'I'
to the resolution of primary viremia (mirrored in our infant by lowered HIV- 1111i:::I'
replication from ART) and establishment of chronic infection. 11111:
iilll
l11
ilill
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G. HIV-specific CD4+ T cells and relationship with HIV-1 replication.
The past five years have seen marked progress in the study of HIV-specific
CD4+ T cell populations, and how the frequency and function of these cells relate
to HIV-1 replication. A cross-sectional study of HIV-1 p24-specific CD4+ T cell
proliferative responses found an inverse relationship between the presence of
proliferative responses and plasma HIV-1 RNA in therapy-na ive, chronically-
infected adults (39). The absence of HIV-specific CD4+ T cell proliferation in
viremic individuals suggested the loss or dysfunction of these cells as a
consequence of concurrent HIV- replication. Later, using a flow-based
intracellular cytokine staining assay, HIV-specific CD4+ T cells producing IFN-
were detected ex vivo in adults with progressive HIV-1 infection (41). HIV-1 gag-
specific CD4+ T cells were more commonly detected and were detected at higher
frequencies in HIV-1 progressors than in individuals with undetectable plasma
HIV-1 loads, although no significant relationship between plasma HIV-1 RNA and
the frequency of HIV-specific CD4+ T cell responses was observed. These data
demonstrated that HIV-specific CD4+ T cells are not depleted from the circulation
of individuals with long-standing HIV-1 replication. Recently, at least 2 groups
have described the detection of IFN- producing HIV-specific CD4+ T cells but
diminished in vitro proliferative responses in individuals with ongoing HIV-
replication , clarifying the seemingly discordant previous findings (44 , 45). In long-
term non-progressors (L TNP) with controlled HIV-1 replication , HIV-specific CD4+
cell IFN- responses were found concurrently with HIV- proliferative
responses. The lack of proliferative responses in adults with progressive HIV-
infection suggested a specific functional defect in HIV-specific CD4+ T cells.
Available data suggest the selective impairment of HIV-specific T cell
responses in early vertical infection. We have previously demonstrated the
delayed generation of HIV-specific CD8+ T cells in young infants (47, 49) and that
HIV-specific CD4+ and CD8+ T cell responses are infrequently detected in the
circulation of children who receive potent combination ART in the first few
months of life (27). Until recently, however, most children did not receive early
suppressive ART and persistently high plasma HIV- loads have been
documented over the first several years of life (24). Robust viral replication in the
setting of a developing immune system may dramatically alter the establishment
and maintenance of HIV-specific CD4+ and CD8+ T cell effector and memory cell
111
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populations.
Most prior studies have not documented a strong relationship between CD4+
Ili!il
,"11
:!ilil
liiil
T cell responses and viral load (41, 42, 44, 45, 69). Pitcher et al. documented a
111111
II!::I'
jllli
difference in the frequency of HIV-specific CD4+ T celllFN-y responses between III
111111
adults with active replication and those with long-term suppressed HIV- Ill!i
I;'I
replication , but this difference was not statistically significant (41). We feel there IIiJII
are several reasons why such a relationship was not observed in previous
Ilflll
III
11111
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reports. First, several stud ies focused on H IV - infected long-term non-
progressors and compared the frequency of HIV-specific CD4+ T cells in these
1111
1111:
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individuals to those found in active HIV-1 progressors (42, 44, 69). Several :111II!I
analyses have presented evidence of ongoing HIV-1 replication in L TNP despite
undetectable plasma HIV-1 loads by standard quantitation assays (57 , 70). The
study of L TNP individuars may have minimized the differences in observed HIV-
specific CD4 + T cell frequencies when compared to individuals with progressive
j,-,
infection. Secondly, some studies used routine (limit of detection = 400 RNA
copies/mL) rather than ultrasensitive (limit of detection = 50 RNA copies/mL)
assays for the quantitation of plasma HIV-1 RNA, thereby making it likely that low
levels of HIV-1 replication were not detected (41, 42, 45). Finally, not all plasma
HIV-1 RNA is replication competent and it could be that HIV-specific CD4+ T cell
frequencies correlate better with measures of recent replication events. Future
studies that utilize high-resolution analysis of recent replication events or plasma
HIV-1 load may continue to clarify the relationship between ongoing HIV-
11;11
II'i.
lilll
replication and the frequency of HIV-specific CD4+ T cells IFN-y responses. ij.1I
'Ii
Aside from L TNP individuals , many studies have described weak or absent
!il
HIV-specific CD4+ T cell proliferative responses in viremic adults who did not
lUll
; !
!il
receive ART during acute infection (39, 40, 44, 71). By contrast, the present
study detected HIV-specific CD4+ T cell proliferative responses in children who
III!!
III;
I:I'
did not receive ART during acute HIV-1 infection. Responses were primarily I!:w
detected in children with plasma HIV-1 RNA 0:50 copies/mL. These data suggest
Iffll
..11
I"l
1i'
that the major factor associated with reduced in vitro proliferative capacity is the 11'
presence of vigorous ongoing viral replication and that control of viral replication ili
may allow the reversal of the proliferative defect. In this regard , the limited
proliferative capacity of HIV-specific CD4+ T cells may be similar to those
ill
III
'II
::1
described in other virus-specific CD4+ T cell responses during acute infection
(72).
100
There are several potential mechanisms to explain diminished in vitro p55-
specific CD4+ T cell proliferation in children with ongoing HIV-1 replication. The
recent demonstration by Douek et al. that HIV-specific CD4+ T cells are
preferentially infected by HIV- raises the possibility that the absence of
proliferative responses in viremic individuals may be a direct consequence of
HIV-1 infection (73). Sieg and colleagues have reported that diminished CD4+ T
cell proliferation in HIV- infected individuals is associated with reduced expression
of several cell cycle proteins, resulting in early G arrest (74). Observed
imbalances in T cell nucleoside pools in HIV- infected individuals may inhibit
normal cellular proliferation (75). Finally, continuous exposure of HIV-specific
CD4+ T cells in chronically-viremic persons may allow "clonal exhaustion" that
preclude the abilty of these cells to proliferate in vitro and possibly, in vivo.
H. HIV-specifc T cell immunity and HIV-1 replication
The data presented in this dissertation have detected and characterized both
CD8+ and CD4+ T cell responses in pediatric subjects. The dependence of both
arms of the T cell immune response on active HIV-1 replication to drive and
maintain effector populations supports the use of HIV-1 antigens to immunize
infants and children. It is abundantly clear, however, that traditional vaccination
methods must be used to boost HIV-specific immunity. Structured therapy
interruptions have been explored as a means of "auto-vaccinating" an individual
to boost HIV-specific immune responses. While the merits of these treatments
;:-
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are debatable , the loss of CD4+ T cell proliferative capacity in viremic individuals
may not allow for the establishment of long-lived CD4+ and CD8+ T cell immunity.
Furthermore, the preservation of CMV-specific CD4+ T cell populations 
children with suppressed HIV-1 replication supports the use of combination ART
when possible.
,. Conclusion.
The experiments detailed in this thesis dissertation have contributed to a
!liii
lii
IIII1
:jil
iill
i.:1more complete understanding of the timing, intensity, and breadth of pediatric T
ilil
cell responses targeted against HIV-1. Specifically, the frequency and hierarchy
of HIV-1-specific CD8+ T cells in vertically-infected infants were defined.
Iii!
11;1
II:
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Significant relationships between the presence, breadth, and intensity of HIV-
specific CD8+ T cell responses and age and HIV- replication were noted.
I,ll
1111
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Furthermore, these data indicate that the HIV-1 accessory proteins play an
important role in the pediatric CD8+ T cell response against HIV-1, and vaccine
a\i!
1:1
ill
ill'
iii'
strategies may benefit from the inclusion of these immunogenic proteins. The ii,
role of epitope escape in pediatric infection was explored in a single infant with a
dramatic shift in epitope usage during the first 2 years of life. The lack of escape
mutation within epitope sequences suggests that alternative mechanisms, such
as antigen processing or regulation of viral protein expression , may influence the
specificity and timing of early HIV-specific CD8+ T cell responses. Finally, HIV-
specific CD4+ T cell responses were studied in a large cohort of vertically-
102
infected children. The results of this study reveal a relationship between HIV-
replication and the presence of HIV-1-specific CD4+ T cells, a relationship not
reported in any previous study, pediatric or adult. The lack of CMV-specific CD4+
T cell IFN-y responses , as well as HIV-specific CD4+ proliferative responses in
children with progressive HIV-1 infection reaffirms the benefit of antiretroviral
therapy and argues against therapy interruption schemes that may deteriorate
antigen-specific CD4 + T cell responses.
Ilii
In conclusion , data presented in this dissertation ilustrate that HIV-specific T
;lli
ill
Iiicell immune responses may be detected in vertically-infected infants and
ill
IIIchildren. Vaccine strategies to prime and/or boost HIV-specific cellular immunity
in vertically- infected infants and children may allow for continued control of HIV-
replication through current therapy strategies and perhaps offer the hope that
III
therapy may be removed as effective HIV-specific cellular responses are
i::1
mounted.
III
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